Human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tat	I-protein
upregulates	O
interleukin-2	B-protein
secretion	O
in	O
activated	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

Dysregulation	O
of	O
cytokines	B-protein
secreted	O
by	O
T	B-cell_type
cells	I-cell_type
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
AIDS	O
.	O

To	O
investigate	O
the	O
effects	O
of	O
human	B-protein
immunodeficiency	I-protein
virus	I-protein
type	I-protein
1	I-protein
(	I-protein
HIV-1	I-protein
)	I-protein
Tat	I-protein
on	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
expression	O
,	O
we	O
used	O
IL-2	B-DNA
promoter-chloramphenicol	I-DNA
acetyltransferase	I-DNA
constructs	I-DNA
and	O
IL-2-secreting	B-cell_line
Jurkat	I-cell_line
T	I-cell_line
cells	I-cell_line
as	O
a	O
model	O
system	O
.	O

Transient	O
expression	O
of	O
HIV-1	B-protein
Tat	I-protein
induced	O
a	O
five-	O
to	O
eightfold	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
in	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
with	O
phytohemagglutinin	B-protein
and	O
phorbol	O
myristate	O
acetate	O
.	O

IL-2	B-protein
secretion	O
was	O
increased	O
more	O
than	O
twofold	O
in	O
both	O
Jurkat	B-cell_line
T	I-cell_line
cells	I-cell_line
and	O
primary	B-cell_line
T	I-cell_line
cells	I-cell_line
stimulated	O
by	O
extracellular	B-protein
HIV-1	I-protein
Tat	I-protein
protein	I-protein
.	O

Analysis	O
of	O
mRNA	B-RNA
suggested	O
that	O
Tat	O
exerts	O
its	O
effect	O
on	O
IL-2	B-protein
primarily	O
at	O
the	O
transcriptional	O
level	O
.	O

The	O
NF-kappa	B-DNA
B	I-DNA
site	I-DNA
at	O
positions	O
-206	B-DNA
to	I-DNA
-195	I-DNA
of	O
the	O
IL-2	B-DNA
promoter	I-DNA
was	O
required	O
but	O
not	O
sufficient	O
for	O
the	O
Tat	B-protein
effect	O
.	O

The	O
Tat	B-protein
-mediated	O
increase	O
in	O
IL-2	B-DNA
promoter	I-DNA
activity	O
could	O
selectively	O
be	O
blocked	O
by	O
antisense	O
tat	O
or-unlike	O
the	O
analogous	O
effect	O
of	O
human	B-protein
T-cell	I-protein
lymphotropic	I-protein
virus	I-protein
type	I-protein
1	I-protein
Tax	I-protein
-by	O
cyclosporin	O
A	O
.	O

The	O
observed	O
increase	O
in	O
IL-2	B-protein
levels	O
might	O
facilitate	O
virus	O
spread	O
from	O
or	O
to	O
T	B-cell_type
cells	I-cell_type
.	O

Furthermore	O
,	O
it	O
might	O
contribute	O
to	O
the	O
hypergammaglobulinemia	O
or	O
,	O
together	O
with	O
other	O
cytokines	B-protein
found	O
to	O
be	O
dysregulated	O
,	O
the	O
T-helper	O
cell	O
dysfunctions	O
observed	O
in	O
AIDS	O
patients	O
.	O

JOURNAL	NULL
OF	NULL
VIROLOGY	NULL
,	NULL
July	NULL
1994	NULL
,	NULL
p.	NULL
4177-4185	NULL
0022-538	NULL
X	NULL
,	NULL
/94/	NULL
$	NULL
04.00+0	NULL
Copyright	NULL
Â©	NULL
1994	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
Vol	NULL
.	NULL

68	NULL
,	NULL
No	NULL
.	NULL

7	NULL
Human	NULL
Immunodeficiency	NULL
Virus	NULL
Type	NULL
1	NULL
Tat	NULL
Upregulates	NULL
Interleukin-2	NULL
Secretion	NULL
in	NULL
Activated	NULL
T	NULL
Cells	NULL
MICHAEL	NULL
O.	NULL
WESTENDORP	NULL
,	NULL
'	NULL
MIN	NULL
LI-WEBER	NULL
,	NULL
'	NULL
RAINER	NULL
W.	NULL
FRANK	NULL
,	NULL
``	NULL
anp	NULL
PETER	NULL
H.	NULL
KRAMMER'*	NULL
Division	NULL
of	NULL
Immunogenetics	NULL
,	NULL
Tumorimmunology	NULL
Program	NULL
,	NULL
German	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
``	NULL
and	NULL
Center	NULL
of	NULL
Molecular	NULL
Biology	NULL
,	NULL
University	NULL
of	NULL
Heidelberg	NULL
,	NULL
``	NULL
D-69120	NULL
Heidelberg	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
Received	NULL
10	NULL
June	NULL
1993/Accepted	NULL
6	NULL
April	NULL
1994	NULL
Dysregulation	NULL
of	NULL
cytokines	NULL
secreted	NULL
by	NULL
T	NULL
cells	NULL
may	NULL
play	NULL
an	NULL
important	NULL
role	NULL
in	NULL
the	NULL
pathogenesis	NULL
of	NULL
AIDS	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
effects	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
Tat	NULL
on	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
expression	NULL
,	NULL
we	NULL
used	NULL
IL-2	NULL
promoter-chloramphenicol	NULL
acetyltransferase	NULL
constructs	NULL
and	NULL
IL-2-secreting	NULL
Jurkat	NULL
T	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
system	NULL
.	NULL

Transient	NULL
expression	NULL
of	NULL
HIV-1	NULL
Tat	NULL
induced	NULL
a	NULL
five-	NULL
to	NULL
eightfold	NULL
increase	NULL
in	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
stimulated	NULL
with	NULL
phytohemagglutinin	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
.	NULL

IL-2	NULL
secretion	NULL
was	NULL
increased	NULL
more	NULL
than	NULL
twofold	NULL
in	NULL
both	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
primary	NULL
T	NULL
cells	NULL
stimulated	NULL
by	NULL
extracellular	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
.	NULL

Analysis	NULL
of	NULL
mRNA	NULL
suggested	NULL
that	NULL
Tat	NULL
exerts	NULL
its	NULL
effect	NULL
on	NULL
IL-2	NULL
primarily	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

The	NULL
NF-B	NULL
site	NULL
at	NULL
positions	NULL
-206	NULL
to	NULL
-195	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
required	NULL
but	NULL
not	NULL
sufficient	NULL
for	NULL
the	NULL
Tat	NULL
effect	NULL
.	NULL

The	NULL
Tat-mediated	NULL
increase	NULL
in	NULL
IL-2	NULL
promoter	NULL
activity	NULL
could	NULL
selectively	NULL
be	NULL
blocked	NULL
by	NULL
antisense	NULL
tat	NULL
or-unlike	NULL
the	NULL
analogous	NULL
effect	NULL
of	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
1	NULL
Tax-by	NULL
cyclosporin	NULL
A	NULL
.	NULL

The	NULL
observed	NULL
increase	NULL
in	NULL
IL-2	NULL
levels	NULL
might	NULL
facilitate	NULL
virus	NULL
spread	NULL
from	NULL
or	NULL
to	NULL
T	NULL
cells	NULL
.	NULL

Furthermore	NULL
,	NULL
it	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
hypergammaglobulinemia	NULL
or	NULL
,	NULL
together	NULL
with	NULL
other	NULL
cytokines	NULL
found	NULL
to	NULL
be	NULL
dysregulated	NULL
,	NULL
the	NULL
T-helper	NULL
cell	NULL
dysfunctions	NULL
observed	NULL
in	NULL
AIDS	NULL
patients	NULL
.	NULL

Transactivation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
(	NULL
HIV-1	NULL
)	NULL
gene	NULL
expression	NULL
by	NULL
HIV-1	NULL
Tat	NULL
nuclear	NULL
protein	NULL
has	NULL
previously	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
(	NULL
10	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Tat	NULL
binds	NULL
to	NULL
a	NULL
pyrimidine	NULL
bulge	NULL
in	NULL
the	NULL
stem-loop	NULL
of	NULL
the	NULL
transactivation	NULL
response	NULL
(	NULL
TAR	NULL
)	NULL
RNA	NULL
structure	NULL
found	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
all	NULL
HIV-1	NULL
mRNAs	NULL
.	NULL

Furthermore	NULL
,	NULL
cellular	NULL
proteins	NULL
and	NULL
transcription	NULL
factors	NULL
are	NULL
required	NULL
for	NULL
efficient	NULL
gene	NULL
expression	NULL
from	NULL
the	NULL
HIV-1	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
LTR	NULL
)	NULL
and	NULL
interact	NULL
with	NULL
Tat	NULL
(	NULL
21	NULL
,	NULL
49	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
suggest	NULL
that	NULL
Tat	NULL
acts	NULL
as	NULL
a	NULL
processivity	NULL
factor	NULL
and	NULL
promotes	NULL
RNA	NULL
transcript	NULL
elongation	NULL
(	NULL
16	NULL
)	NULL
,	NULL
although	NULL
augmentation	NULL
of	NULL
transcript	NULL
initiation	NULL
has	NULL
also	NULL
been	NULL
suggested	NULL
(	NULL
25	NULL
)	NULL
.	NULL

According	NULL
to	NULL
the	NULL
model	NULL
of	NULL
Cullen	NULL
(	NULL
11	NULL
)	NULL
,	NULL
Tat	NULL
has	NULL
no	NULL
direct	NULL
effect	NULL
on	NULL
the	NULL
processivity	NULL
of	NULL
transcription	NULL
complexes	NULL
that	NULL
initiate	NULL
at	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Instead	NULL
,	NULL
it	NULL
may	NULL
simply	NULL
activate	NULL
initiation	NULL
of	NULL
transcription	NULL
from	NULL
an	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
that	NULL
is	NULL
intrinsically	NULL
elongation	NULL
competent	NULL
.	NULL

Thus	NULL
,	NULL
activation	NULL
of	NULL
transcript	NULL
initiation	NULL
may	NULL
be	NULL
masked	NULL
as	NULL
enhanced	NULL
elongation	NULL
.	NULL

Recent	NULL
evidence	NULL
suggests	NULL
that	NULL
Tat	NULL
may	NULL
mediate	NULL
additional	NULL
activities	NULL
regarding	NULL
cell	NULL
growth	NULL
and	NULL
function	NULL
.	NULL

Thus	NULL
,	NULL
Tat	NULL
was	NULL
found	NULL
to	NULL
stimulate	NULL
growth	NULL
of	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
cells	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
and	NULL
caused	NULL
Kaposi	NULL
's	NULL
sarcoma-like	NULL
dermal	NULL
lesions	NULL
in	NULL
some	NULL
tat-transgenic	NULL
mice	NULL
(	NULL
62	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
Tat	NULL
was	NULL
reported	NULL
to	NULL
suppress	NULL
antigen-induced	NULL
but	NULL
not	NULL
phytohemagglutinin	NULL
(	NULL
PHA	NULL
)	NULL
induced	NULL
proliferation	NULL
of	NULL
T	NULL
cells	NULL
(	NULL
61	NULL
)	NULL
.	NULL

The	NULL
tax	NULL
gene	NULL
product	NULL
of	NULL
human	NULL
T-cell	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
(	NULL
HTLV-I	NULL
)	NULL
is	NULL
a	NULL
functional	NULL
analog	NULL
of	NULL
Tat	NULL
and	NULL
transactivates	NULL
viral	NULL
gene	NULL
expression	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
Tax	NULL
activates	NULL
cellular	NULL
gene	NULL
expression	NULL
(	NULL
63	NULL
)	NULL
,	NULL
including	NULL
expression	NULL
of	NULL
genes	NULL
like	NULL
the	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
,	NULL
the	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
(	NULL
TGF-B	NULL
)	NULL
,	NULL
and	NULL
the	NULL
IL-2	NULL
receptor	NULL
genes	NULL
(	NULL
9	NULL
,	NULL
31	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Recent	NULL
studies	NULL
suggest	NULL
that	NULL
Tat	NULL
,	NULL
like	NULL
Tax	NULL
,	NULL
also	NULL
transactivates	NULL
cellular	NULL
genes	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
genes	NULL
of	NULL
the	NULL
cytokines	NULL
TGF-B	NULL
(	NULL
36	NULL
)	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
(	NULL
4	NULL
)	NULL
,	NULL
and	NULL
IL-6	NULL
.	NULL

Repression	NULL
of	NULL
gene	NULL
expression	NULL
by	NULL
Tat	NULL
has	NULL
also	NULL
been	NULL
demon	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
Tumorimmunology	NULL
Program	NULL
,	NULL
Division	NULL
730	NULL
,	NULL
German	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
D-69120	NULL
Heidelberg	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
.	NULL

Phone	NULL
:	NULL
49-6221-423717	NULL
.	NULL

Fax	NULL
:	NULL
49-6221-411715	NULL
.	NULL

4177	NULL
strated	NULL
,	NULL
for	NULL
example	NULL
,	NULL
for	NULL
the	NULL
major	NULL
histocompatibility	NULL
complex	NULL
class	NULL
I	NULL
gene	NULL
(	NULL
26	NULL
)	NULL
and	NULL
the	NULL
manganese	NULL
superoxide	NULL
dismutase	NULL
gene	NULL
(	NULL
18	NULL
)	NULL
.	NULL

Tat	NULL
is	NULL
secreted	NULL
from	NULL
HIV-1-infected	NULL
or	NULL
fat-trans-fected	NULL
cells	NULL
and	NULL
can	NULL
be	NULL
immunoprecipitated	NULL
from	NULL
the	NULL
supernatant	NULL
of	NULL
such	NULL
cells	NULL
(	NULL
15	NULL
,	NULL
19	NULL
)	NULL
.	NULL

Exogenous	NULL
Tat	NULL
is	NULL
readily	NULL
endocy-tosed	NULL
and	NULL
targeted	NULL
to	NULL
the	NULL
nucleus	NULL
of	NULL
cells	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
observations	NULL
suggest	NULL
that	NULL
Tat	NULL
may	NULL
activate	NULL
expression	NULL
of	NULL
cellular	NULL
genes	NULL
in	NULL
infected	NULL
and	NULL
noninfected	NULL
cells	NULL
and	NULL
therefore	NULL
contribute	NULL
to	NULL
the	NULL
cytokine	NULL
dysregulation	NULL
observed	NULL
in	NULL
the	NULL
course	NULL
of	NULL
an	NULL
HIV-1	NULL
infection	NULL
(	NULL
6	NULL
)	NULL
.	NULL

IL-2	NULL
has	NULL
a	NULL
pivotal	NULL
role	NULL
in	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Originally	NULL
described	NULL
as	NULL
a	NULL
T-cell	NULL
growth	NULL
factor	NULL
(	NULL
40	NULL
)	NULL
,	NULL
IL-2	NULL
is	NULL
known	NULL
to	NULL
have	NULL
direct	NULL
effects	NULL
on	NULL
growth	NULL
and	NULL
differentiation	NULL
of	NULL
T	NULL
and	NULL
B	NULL
lym-phocytes	NULL
,	NULL
natural	NULL
killer	NULL
cells	NULL
,	NULL
lymphokine-activated	NULL
killer	NULL
(	NULL
LAK	NULL
)	NULL
cells	NULL
,	NULL
monocytes	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
oligodendrocytes	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
dysregulation	NULL
of	NULL
IL-2	NULL
expression	NULL
by	NULL
Tat	NULL
may	NULL
have	NULL
important	NULL
consequences	NULL
on	NULL
the	NULL
pathogenesis	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

In	NULL
this	NULL
study	NULL
,	NULL
we	NULL
describe	NULL
the	NULL
use	NULL
of	NULL
IL-2	NULL
promoter-chloramphenicol	NULL
acetyltransferase	NULL
(	NULL
CAT	NULL
)	NULL
constructs	NULL
and	NULL
IL-2-secreting	NULL
Jurkat	NULL
T	NULL
cells	NULL
as	NULL
a	NULL
model	NULL
system	NULL
and	NULL
report	NULL
that	NULL
endogenous	NULL
and	NULL
exogenous	NULL
Tat	NULL
enhance	NULL
IL-2	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
lines	NULL
and	NULL
culture	NULL
conditions	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
and	NULL
HeLa	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
50	NULL
pug	NULL
of	NULL
gentamycin	NULL
per	NULL
ml	NULL
,	NULL
6	NULL
mM	NULL
HEPES	NULL
(	NULL
N-2'-hydroxyethylpiperazine-N'-2-ethanesulfonic	NULL
acid	NULL
)	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
L-glutamine	NULL
at	NULL
37Â°C	NULL
in	NULL
a	NULL
humidified	NULL
atmosphere	NULL
containing	NULL
5	NULL
%	NULL
carbon	NULL
dioxide	NULL
in	NULL
air	NULL
.	NULL

A	NULL
HeLa	NULL
cell	NULL
line	NULL
stably	NULL
expressing	NULL
HIV-1	NULL
Tat	NULL
(	NULL
60	NULL
)	NULL
,	NULL
kindly	NULL
provided	NULL
by	NULL
K.	NULL
Valerie	NULL
(	NULL
Smith	NULL
,	NULL
Kline	NULL
and	NULL
French	NULL
Laboratories	NULL
,	NULL
King	NULL
of	NULL
Prussia	NULL
,	NULL
Pa.	NULL
)	NULL
,	NULL
was	NULL
used	NULL
for	NULL
cocultures	NULL
.	NULL

Preparation	NULL
of	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
heparinized	NULL
peripheral	NULL
blood	NULL
by	NULL
Ficoll	NULL
(	NULL
Biochrom	NULL
,	NULL
Berlin	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
density	NULL
gradient	NULL
centrifugation	NULL
.	NULL

Cells	NULL
were	NULL
washed	NULL
twice	NULL
4178	NULL
WESTENDORP	NULL
ET	NULL
AL	NULL
.	NULL

with	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
PBS	NULL
)	NULL
,	NULL
and	NULL
adherent	NULL
cells	NULL
were	NULL
removed	NULL
by	NULL
incubation	NULL
in	NULL
supplemented	NULL
medium	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37Â°C	NULL
.	NULL

CD19*	NULL
cells	NULL
were	NULL
depleted	NULL
with	NULL
the	NULL
MACS	NULL
magnetic	NULL
microbead	NULL
system	NULL
(	NULL
Miltenyi	NULL
Biotech	NULL
,	NULL
Bergisch	NULL
Gladbach	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

Purity	NULL
was	NULL
>	NULL
99	NULL
%	NULL
as	NULL
assessed	NULL
by	NULL
cytoffluorometry	NULL
with	NULL
an	NULL
anti-CD2	NULL
antibody	NULL
(	NULL
clone	NULL
39C1.5	NULL
;	NULL
Immunotech	NULL
,	NULL
Mar-seilles	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Ten	NULL
nanograms	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
(	NULL
Sigma	NULL
,	NULL
Deisenhofen	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
per	NULL
milliliter	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
PHA	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
mi	NULL
were	NULL
used	NULL
for	NULL
mitogen	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
.	NULL

Recombinant	NULL
plasmids	NULL
.	NULL

The	NULL
HindIII	NULL
fragment	NULL
of	NULL
pIL-2/	NULL
CAT	NULL
(	NULL
52	NULL
)	NULL
containing	NULL
the	NULL
complete	NULL
IL-2	NULL
promoter-enhancer	NULL
region	NULL
from	NULL
positions	NULL
-575	NULL
to	NULL
+47	NULL
was	NULL
inserted	NULL
into	NULL
the	NULL
HindIII	NULL
site	NULL
of	NULL
pBLCAT3	NULL
(	NULL
37	NULL
)	NULL
in	NULL
both	NULL
orientations	NULL
to	NULL
yield	NULL
pIL-2/CAT	NULL
and	NULL
pIL-2/CAT-	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
HIV-1	NULL
expression	NULL
vector	NULL
pEXCMV-Tat	NULL
contained	NULL
the	NULL
tat	NULL
cDNA	NULL
from	NULL
pCV1	NULL
(	NULL
1	NULL
)	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
cytomegalovirus	NULL
immediate-early	NULL
promoter	NULL
,	NULL
the	NULL
simian	NULL
virus	NULL
40	NULL
splice	NULL
signal	NULL
sequence	NULL
(	NULL
positions	NULL
4710	NULL
to	NULL
4100	NULL
)	NULL
,	NULL
and	NULL
the	NULL
polyadenylation	NULL
signal	NULL
(	NULL
positions	NULL
2770	NULL
to	NULL
2533	NULL
)	NULL
.	NULL

The	NULL
HIV-1	NULL
LTR	NULL
was	NULL
cloned	NULL
as	NULL
a	NULL
Xhol-HindIlI	NULL
fragment	NULL
of	NULL
the	NULL
HIV-1	NULL
cDNA	NULL
clone	NULL
C15	NULL
into	NULL
pSVIXCAT	NULL
(	NULL
55	NULL
)	NULL
to	NULL
yield	NULL
pHIV-1	NULL
LTR/CAT	NULL
.	NULL

pRK	NULL
was	NULL
used	NULL
for	NULL
expression	NULL
of	NULL
HTLV-I	NULL
Tax	NULL
,	NULL
and	NULL
pHTLV-I/CAT	NULL
was	NULL
used	NULL
as	NULL
a	NULL
reporter	NULL
construct	NULL
.	NULL

The	NULL
plasmid	NULL
containing	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
sequence	NULL
from	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
light-chain	NULL
enhancer	NULL
was	NULL
generated	NULL
by	NULL
ligation	NULL
of	NULL
the	NULL
synthesized	NULL
NF-kB	NULL
binding	NULL
sequence	NULL
5Â¢-CAGAGGGGACTTTCCGAGAGGC-3	NULL
'	NULL
(	NULL
34	NULL
)	NULL
into	NULL
the	NULL
polylinker	NULL
site	NULL
of	NULL
pBLCAT2	NULL
(	NULL
37	NULL
)	NULL
.	NULL

A	NULL
construct	NULL
containing	NULL
five	NULL
copies	NULL
of	NULL
the	NULL
sequence	NULL
GATTITTCACCTAAATC-3	NULL
'	NULL
(	NULL
positions	NULL
-215	NULL
to	NULL
-191	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
)	NULL
inserted	NULL
in	NULL
pBLCAT2	NULL
was	NULL
obtained	NULL
from	NULL
E.	NULL
Serfling	NULL
,	NULL
University	NULL
of	NULL
Wiirzburg	NULL
,	NULL
Wiirzburg	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
(	NULL
5xTCEd	NULL
[	NULL
50	NULL
]	NULL
)	NULL
.	NULL

The	NULL
antisense-fat	NULL
expression	NULL
construct	NULL
(	NULL
pAS-tat	NULL
)	NULL
pAR6	NULL
and	NULL
the	NULL
antisense-HIV-1	NULL
gag	NULL
plasmid	NULL
(	NULL
pAS-gag	NULL
)	NULL
pAR2	NULL
(	NULL
45	NULL
)	NULL
are	NULL
pKEX	NULL
derivatives	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Transfection	NULL
experiments	NULL
.	NULL

Plasmid	NULL
DNA	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
as	NULL
described	NULL
by	NULL
Gorman	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
1.5	NULL
%	NULL
10	NULL
``	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
total	NULL
of	NULL
15	NULL
ug	NULL
of	NULL
plasmid	NULL
DNA	NULL
in	NULL
500	NULL
pug	NULL
of	NULL
DEAE-dextran	NULL
and	NULL
20	NULL
ug	NULL
of	NULL
chloroquine	NULL
per	NULL
ml	NULL
for	NULL
30	NULL
min	NULL
.	NULL

For	NULL
stimulation	NULL
,	NULL
cultures	NULL
were	NULL
treated	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
PMA	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
and	NULL
5	NULL
ug	NULL
of	NULL
PHA	NULL
(	NULL
Sigma	NULL
)	NULL
per	NULL
ml	NULL
.	NULL

Approximately	NULL
40	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
the	NULL
clarified	NULL
lysates	NULL
were	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
(	NULL
22	NULL
)	NULL
by	NULL
using	NULL
an	NULL
automatic	NULL
thin-layer	NULL
chromatography	NULL
linear	NULL
analyzer	NULL
(	NULL
Berthold	NULL
,	NULL
Wildbad	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

All	NULL
percent	NULL
conversion	NULL
values	NULL
were	NULL
corrected	NULL
for	NULL
differences	NULL
in	NULL
total	NULL
protein	NULL
concentration	NULL
among	NULL
samples	NULL
by	NULL
using	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
system	NULL
.	NULL

Mutations	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Mutants	NULL
with	NULL
deletions	NULL
of	NULL
the	NULL
5	NULL
end	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
were	NULL
synthesized	NULL
by	NULL
PCR	NULL
according	NULL
to	NULL
standard	NULL
protocols	NULL
(	NULL
29	NULL
)	NULL
with	NULL
primers	NULL
containing	NULL
a	NULL
HindIII	NULL
or	NULL
a	NULL
BamHI	NULL
restriction	NULL
site	NULL
.	NULL

The	NULL
resulting	NULL
PCR	NULL
products	NULL
were	NULL
HindIII-BamHI	NULL
digested	NULL
and	NULL
cloned	NULL
into	NULL
pBLCAT3	NULL
.	NULL

An	NULL
NF-kB	NULL
point	NULL
mutation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
synthesized	NULL
by	NULL
thermal	NULL
cycle	NULL
fusion	NULL
PCR	NULL
(	NULL
29	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide	NULL
primers	NULL
TCACCTACATCC-3	NULL
'	NULL
and	NULL
5-GGATGTAGGTGAAATAAA	NULL
TCTTITGTTACATTAGC-3	NULL
'	NULL
were	NULL
used	NULL
to	NULL
introduce	NULL
a	NULL
-204GGG-to-TTT	NULL
base	NULL
substitution	NULL
within	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
motif	NULL
.	NULL

The	NULL
integrity	NULL
of	NULL
all	NULL
IL-2	NULL
promoter	NULL
mutants	NULL
was	NULL
confirmed	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
.	NULL

Primer	NULL
extension	NULL
analysis	NULL
.	NULL

Primer	NULL
extension	NULL
analysis	NULL
was	NULL
based	NULL
on	NULL
the	NULL
method	NULL
described	NULL
by	NULL
Contente	NULL
et	NULL
al	NULL
.	NULL

(	NULL
8	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
RNA	NULL
(	NULL
3	NULL
pug	NULL
)	NULL
was	NULL
isolated	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
J.	NULL
ViroL	NULL
.	NULL

transiently	NULL
cotransfected	NULL
with	NULL
pIL-2/CAT	NULL
and	NULL
ptat	NULL
or	NULL
pIL-2/	NULL
CAT	NULL
alone	NULL
.	NULL

The	NULL
RNA	NULL
was	NULL
incubated	NULL
with	NULL
0.5	NULL
to	NULL
0.9	NULL
ng	NULL
of	NULL
-labeled	NULL
oligonucleotide	NULL
primer	NULL
(	NULL
binding	NULL
close	NULL
to	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
CAT	NULL
coding	NULL
region	NULL
)	NULL
in	NULL
900	NULL
mM	NULL
NaCl-150	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.6	NULL
)	NULL
-0.3	NULL
mM	NULL
EDTA	NULL
for	NULL
10	NULL
min	NULL
at	NULL
68Â°C	NULL
and	NULL
then	NULL
for	NULL
2	NULL
h	NULL
at	NULL
30Â°C	NULL
.	NULL

The	NULL
annealed	NULL
primer	NULL
was	NULL
then	NULL
precipitated	NULL
with	NULL
ethanol	NULL
;	NULL
resuspended	NULL
in	NULL
20	NULL
wl	NULL
of	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
(	NULL
pH	NULL
8.3	NULL
)	NULL
-75	NULL
mM	NULL
KCI-3	NULL
mM	NULL
MgCl	NULL
;	NULL
-10	NULL
mM	NULL
dithiothreitol-1	NULL
mM	NULL
each	NULL
dATP	NULL
,	NULL
dCTP	NULL
,	NULL
dGTP	NULL
,	NULL
and	NULL
dTTP-1	NULL
U	NULL
of	NULL
RNasin	NULL
(	NULL
Serva	NULL
,	NULL
Heidelberg	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
per	NULL
pl-50	NULL
pg	NULL
of	NULL
RNase	NULL
A	NULL
per	NULL
ml-25	NULL
mM	NULL
EDTA	NULL
for	NULL
30	NULL
min	NULL
at	NULL
37Â°C	NULL
;	NULL
extracted	NULL
with	NULL
phenol-chloroform	NULL
(	NULL
1:1	NULL
,	NULL
vol/vol	NULL
)	NULL
;	NULL
ethanol	NULL
precipitated	NULL
;	NULL
and	NULL
run	NULL
on	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
beside	NULL
a	NULL
DNA	NULL
sequencing	NULL
ladder	NULL
.	NULL

Anti-HIV-1	NULL
Tat	NULL
serum	NULL
.	NULL

Synthesis	NULL
of	NULL
full-length	NULL
HIV-1	NULL
Tat	NULL
(	NULL
86	NULL
amino	NULL
acids	NULL
;	NULL
HIV-1	NULL
strain	NULL
BL16	NULL
)	NULL
will	NULL
be	NULL
described	NULL
in	NULL
detail	NULL
elsewhere	NULL
(	NULL
18a	NULL
)	NULL
.	NULL

Anti-HIV-1	NULL
Tat	NULL
serum	NULL
against	NULL
chemically	NULL
synthesized	NULL
Tat	NULL
(	NULL
sTat	NULL
)	NULL
was	NULL
raised	NULL
in	NULL
rabbits	NULL
.	NULL

Rabbits	NULL
were	NULL
immunized	NULL
six	NULL
times	NULL
with	NULL
150	NULL
mg	NULL
of	NULL
sTat	NULL
at	NULL
3-	NULL
to	NULL
4-week	NULL
intervals	NULL
.	NULL

The	NULL
specific	NULL
anti-Tat	NULL
activity	NULL
was	NULL
determined	NULL
by	NULL
enzyme-linked	NULL
immunosorbent	NULL
assay	NULL
(	NULL
ELISA	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
96-well	NULL
Micro-Test	NULL
plates	NULL
(	NULL
Becton-Dickinson	NULL
,	NULL
Oxnard	NULL
,	NULL
Calif.	NULL
)	NULL
were	NULL
coated	NULL
with	NULL
1	NULL
ug	NULL
of	NULL
sTat	NULL
per	NULL
ml	NULL
or	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
BSA	NULL
)	NULL
as	NULL
a	NULL
control	NULL
at	NULL
4Â°C	NULL
overnight	NULL
.	NULL

Free	NULL
sites	NULL
on	NULL
the	NULL
plates	NULL
were	NULL
blocked	NULL
with	NULL
1X	NULL
PBS	NULL
and	NULL
5	NULL
%	NULL
BSA	NULL
for	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Plates	NULL
were	NULL
washed	NULL
three	NULL
times	NULL
with	NULL
1	NULL
%	NULL
PBS-0.05	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
incubated	NULL
with	NULL
anti-Tat	NULL
or	NULL
control	NULL
serum	NULL
for	NULL
90	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
washed	NULL
as	NULL
described	NULL
above	NULL
,	NULL
incubated	NULL
with	NULL
peroxidase-conjugated	NULL
goat	NULL
anti-rabbit	NULL
antibody	NULL
(	NULL
Dianova	NULL
,	NULL
Hamburg	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
for	NULL
90	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
washed	NULL
as	NULL
described	NULL
above	NULL
,	NULL
and	NULL
developed	NULL
with	NULL
0.1	NULL
M	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
-0.05	NULL
M	NULL
citric	NULL
acid-1.5	NULL
mg	NULL
of	NULL
o-phenylenediamine	NULL
dihydrochloride	NULL
per	NULL
ml-0.03	NULL
%	NULL
H	NULL
;	NULL
,0	NULL
;	NULL
,	NULL
for	NULL
10	NULL
min	NULL
in	NULL
the	NULL
dark	NULL
.	NULL

Tat-containing	NULL
supernatants	NULL
were	NULL
preincu-bated	NULL
with	NULL
anti-Tat	NULL
or	NULL
control	NULL
serum	NULL
for	NULL
2	NULL
h	NULL
at	NULL
37Â°C	NULL
to	NULL
neutralize	NULL
HIV-1	NULL
Tat	NULL
.	NULL

Northern	NULL
(	NULL
RNA	NULL
)	NULL
blotting	NULL
and	NULL
quantification	NULL
of	NULL
IL-2	NULL
.	NULL

Cytoplasmic	NULL
RNA	NULL
was	NULL
isolated	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
by	NULL
using	NULL
the	NULL
Nonidet	NULL
P-40	NULL
lysis	NULL
method	NULL
described	NULL
by	NULL
Gough	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Oligo	NULL
(	NULL
dT	NULL
)	NULL
cellulose	NULL
chromatography	NULL
(	NULL
QuickPrep	NULL
;	NULL
Pharmacia	NULL
,	NULL
Uppsala	NULL
,	NULL
Sweden	NULL
)	NULL
was	NULL
used	NULL
to	NULL
purify	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
.	NULL

RNA	NULL
was	NULL
quantified	NULL
by	NULL
UV	NULL
absorption	NULL
at	NULL
260	NULL
nm	NULL
.	NULL

A	NULL
10-ug	NULL
amount	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
was	NULL
electrophoresed	NULL
in	NULL
1.0	NULL
%	NULL
agarose	NULL
containing	NULL
formaldehyde	NULL
and	NULL
morpholinepropanesulfonic	NULL
acid	NULL
(	NULL
MOPS	NULL
)	NULL
and	NULL
blotted	NULL
onto	NULL
a	NULL
nylon	NULL
membrane	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
35	NULL
)	NULL
.	NULL

For	NULL
hybridization	NULL
(	NULL
47	NULL
)	NULL
,	NULL
probes	NULL
for	NULL
B-actin	NULL
(	NULL
7	NULL
)	NULL
and	NULL
IL-2	NULL
(	NULL
56	NULL
)	NULL
were	NULL
labeled	NULL
by	NULL
the	NULL
3'-end-labeling	NULL
system	NULL
(	NULL
Boehringer	NULL
,	NULL
Mannheim	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
assayed	NULL
by	NULL
a	NULL
human	NULL
IL-2	NULL
ELISA	NULL
(	NULL
Hoffmann-LaRoche	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

RESULTS	NULL
Effect	NULL
of	NULL
HIV-1	NULL
Tat	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
HIV-1	NULL
Tat	NULL
on	NULL
IL-2	NULL
expression	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
,	NULL
a	NULL
tat	NULL
cDNA	NULL
expression	NULL
vector	NULL
(	NULL
ptat	NULL
)	NULL
and	NULL
the	NULL
reporter	NULL
gene	NULL
construct	NULL
pIL-2/CAT	NULL
were	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
CAT	NULL
expression	NULL
was	NULL
measured	NULL
.	NULL

Figure	NULL
1	NULL
shows	NULL
that	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
pIL-2/CAT	NULL
was	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
like	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
.	NULL

However	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
tat	NULL
expression	NULL
and	NULL
not	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
expression	NULL
vector	NULL
lacking	NULL
tat	NULL
cDNA	NULL
,	NULL
IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
enhanced	NULL
five-	NULL
to	NULL
eightfold	NULL
.	NULL

Mitogen	NULL
(	NULL
PHA	NULL
and	NULL
PMA	NULL
)	NULL
stimulation	NULL
was	NULL
required	NULL
for	NULL
this	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
black	NULL
bars	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
mouse	NULL
IL-2	NULL
promoter	NULL
instead	NULL
VoL	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
30	NULL
C	NULL
-rhHapma	NULL
T	NULL
B	NULL
.pHarpma	NULL
Ã©	NULL
20	NULL
$	NULL
2	NULL
38	NULL
G	NULL
&	NULL
C.	NULL
fol	NULL
E	NULL
107	NULL
x	NULL
T	NULL
T.	NULL
0	NULL
--	NULL
pAtat	NULL
ptat	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Upregulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
tat	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
alone	NULL
(	NULL
-	NULL
)	NULL
or	NULL
cotransfected	NULL
with	NULL
the	NULL
fat	NULL
expression	NULL
vector	NULL
ptat	NULL
or	NULL
an	NULL
equal	NULL
amount	NULL
of	NULL
the	NULL
expression	NULL
vector	NULL
lacking	NULL
the	NULL
fat	NULL
cDNA	NULL
(	NULL
pAtat	NULL
)	NULL
.	NULL

IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
percent	NULL
transacetylation	NULL
in	NULL
a	NULL
CAT	NULL
assay	NULL
.	NULL

The	NULL
average	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
error	NULL
bars	NULL
)	NULL
for	NULL
three	NULL
independent	NULL
transfections	NULL
are	NULL
shown	NULL
.	NULL

-	NULL
PHA/PMA	NULL
,	NULL
no	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
;	NULL
+	NULL
PHA/PMA	NULL
,	NULL
stimulation	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
.	NULL

of	NULL
the	NULL
human	NULL
promoter	NULL
was	NULL
used	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Tat	NULL
transactivation	NULL
was	NULL
promoter	NULL
specific	NULL
,	NULL
as	NULL
a	NULL
B-actin	NULL
promoter-CAT	NULL
reporter	NULL
gene	NULL
construct	NULL
was	NULL
not	NULL
influenced	NULL
by	NULL
cotransfection	NULL
with	NULL
ptat	NULL
(	NULL
see	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
cotransfection	NULL
with	NULL
a	NULL
reporter	NULL
gene	NULL
construct	NULL
carrying	NULL
the	NULL
IL-2	NULL
promoter	NULL
cassette	NULL
in	NULL
the	NULL
opposite	NULL
orientation	NULL
only	NULL
resulted	NULL
in	NULL
background	NULL
CAT	NULL
activity	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

HIV-1	NULL
Tat	NULL
might	NULL
activate	NULL
transcription	NULL
from	NULL
unusual	NULL
initiation	NULL
sites	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
performed	NULL
primer	NULL
extension	NULL
analysis	NULL
to	NULL
map	NULL
the	NULL
RNA	NULL
5	NULL
'	NULL
end	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2	NULL
confirmed	NULL
a	NULL
correctly	NULL
initiated	NULL
,	NULL
IL-2	NULL
promoter-driven	NULL
transcription	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
from	NULL
pIL-2/CAT	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

Thus	NULL
,	NULL
HIV-1	NULL
Tat	NULL
stimulates	NULL
transcription	NULL
from	NULL
the	NULL
previously	NULL
described	NULL
initiation	NULL
site	NULL
at	NULL
position	NULL
+1	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
52	NULL
)	NULL
.	NULL

Selective	NULL
blocking	NULL
with	NULL
fot	NULL
antisense	NULL
RNA	NULL
.	NULL

To	NULL
provide	NULL
tat	NULL
-	NULL
+o	NULL
-	NULL
+	NULL
-	NULL
control	NULL
PHA/PMA	NULL
+	NULL
+	NULL
-	NULL
-	NULL
_-	NULL
sequence	NULL
a	NULL
Wik	NULL
W	NULL
Ih	NULL
+	NULL
h	NULL
-	NULL
.	NULL

ai..	NULL

FIG	NULL
.	NULL

2	NULL
.	NULL

Primer	NULL
extension	NULL
analysis	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
RNA	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
and	NULL
ptat	NULL
(	NULL
tat	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
as	NULL
indicated	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
radioactivity	NULL
were	NULL
loaded	NULL
,	NULL
and	NULL
a	NULL
control	NULL
sequencing	NULL
reaction	NULL
was	NULL
run	NULL
beside	NULL
the	NULL
gel	NULL
to	NULL
allow	NULL
determination	NULL
of	NULL
the	NULL
fragment	NULL
sizes	NULL
.	NULL

+	NULL
,	NULL
present	NULL
;	NULL
-	NULL
,	NULL
absent	NULL
.	NULL

HIV-1	NULL
Tat	NULL
UPREGULATES	NULL
IL-2	NULL
EXPRESSION	NULL
4179	NULL
ptat	NULL
ptat	NULL
+	NULL
pAS-tat	NULL
ptat	NULL
+	NULL
pAS-gag	NULL
ptat	NULL
+	NULL
pKEX	NULL
1	NULL
Ls	NULL
0	NULL
50	NULL
10	NULL
15	NULL
20	NULL
250	NULL
30	NULL
%	NULL
transacetylation	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Selective	NULL
blocking	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
alone	NULL
(	NULL
-	NULL
)	NULL
or	NULL
cotransfected	NULL
with	NULL
the	NULL
indicated	NULL
combinations	NULL
of	NULL
ptat	NULL
,	NULL
a	NULL
pKEX-based	NULL
antisense	NULL
RNA	NULL
expression	NULL
construct	NULL
for	NULL
fat	NULL
(	NULL
pAS-tat	NULL
)	NULL
,	NULL
gag	NULL
(	NULL
pAS-gag	NULL
)	NULL
,	NULL
or	NULL
the	NULL
pKEX	NULL
vector	NULL
itself	NULL
as	NULL
a	NULL
control	NULL
.	NULL

All	NULL
transfectants	NULL
were	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

The	NULL
IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
percent	NULL
transacetylation	NULL
,	NULL
and	NULL
the	NULL
values	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
;	NULL
variation	NULL
was	NULL
less	NULL
than	NULL
14	NULL
%	NULL
.	NULL

independent	NULL
proof	NULL
that	NULL
the	NULL
observed	NULL
augmentation	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
mediated	NULL
by	NULL
Tat	NULL
,	NULL
we	NULL
tried	NULL
to	NULL
selectively	NULL
block	NULL
the	NULL
effect	NULL
.	NULL

Cotransfection	NULL
of	NULL
equal	NULL
amounts	NULL
of	NULL
ptat	NULL
and	NULL
pAS-tat	NULL
,	NULL
expressing	NULL
antisense-fot	NULL
RNA	NULL
,	NULL
selectively	NULL
reduced	NULL
IL-2	NULL
promoter	NULL
activity	NULL
to	NULL
the	NULL
level	NULL
of	NULL
activity	NULL
observed	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Tat	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
blocked	NULL
without	NULL
affecting	NULL
the	NULL
basal	NULL
promoter	NULL
activity	NULL
after	NULL
mitogen	NULL
stimulation	NULL
.	NULL

Two	NULL
further	NULL
controls	NULL
were	NULL
included	NULL
to	NULL
rule	NULL
out	NULL
the	NULL
possibility	NULL
of	NULL
promoter	NULL
interference	NULL
between	NULL
the	NULL
cytomegalovirus	NULL
immediate-early	NULL
promoters	NULL
of	NULL
the	NULL
expression	NULL
vectors	NULL
or	NULL
an	NULL
unspecific	NULL
effect	NULL
of	NULL
antisense	NULL
RNA	NULL
on	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

Neither	NULL
cotransfection	NULL
of	NULL
pKEX	NULL
,	NULL
the	NULL
parent	NULL
vector	NULL
of	NULL
pAS-tat	NULL
,	NULL
nor	NULL
pKEX	NULL
expressing	NULL
antisense-gag	NULL
RNA	NULL
(	NULL
45	NULL
)	NULL
had	NULL
a	NULL
significant	NULL
effect	NULL
on	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Tat	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
data	NULL
support	NULL
the	NULL
interpretation	NULL
that	NULL
fat	NULL
antisense	NULL
RNA	NULL
selectively	NULL
blocks	NULL
Tat	NULL
activity	NULL
.	NULL

The	NULL
transactivator	NULL
protein	NULL
of	NULL
HTLV-I	NULL
,	NULL
termed	NULL
Tax	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
synergize	NULL
with	NULL
mitogenic	NULL
stimuli	NULL
like	NULL
PHA	NULL
and	NULL
PMA	NULL
in	NULL
activating	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
53	NULL
)	NULL
and	NULL
to	NULL
circumvent	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
51	NULL
,	NULL
53	NULL
)	NULL
.	NULL

We	NULL
observed	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
CsA-resistant	NULL
activation	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
PHA-PMA-stimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
by	NULL
HTLV-I	NULL
Tax	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

These	NULL
results	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
previously	NULL
published	NULL
data	NULL
(	NULL
53	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CsA	NULL
treatment	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
cotransfected	NULL
with	NULL
pIL-2/CAT	NULL
and	NULL
ptat	NULL
completely	NULL
blocked	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

Activity	NULL
of	NULL
the	NULL
B-actin	NULL
promoter	NULL
,	NULL
included	NULL
as	NULL
a	NULL
control	NULL
to	NULL
rule	NULL
out	NULL
possible	NULL
toxic	NULL
effects	NULL
of	NULL
CsA	NULL
,	NULL
was	NULL
not	NULL
affected	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
.	NULL

Effect	NULL
of	NULL
HIV-1	NULL
Tat	NULL
and	NULL
HTLV-I	NULL
Tax	NULL
on	NULL
NF-KB	NULL
activity	NULL
.	NULL

To	NULL
test	NULL
the	NULL
assumption	NULL
that	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tat	NULL
and	NULL
Tax	NULL
may	NULL
follow	NULL
different	NULL
mechanisms	NULL
,	NULL
we	NULL
compared	NULL
the	NULL
effects	NULL
of	NULL
HIV-1	NULL
Tat	NULL
and	NULL
HTLV-I	NULL
Tax	NULL
on	NULL
NF-kB	NULL
activity	NULL
,	NULL
known	NULL
to	NULL
be	NULL
increased	NULL
by	NULL
Tax	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effects	NULL
of	NULL
Tax	NULL
and	NULL
Tat	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
reporter	NULL
gene	NULL
construct	NULL
carrying	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
motif	NULL
from	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
light-chain	NULL
enhancer	NULL
(	NULL
Â«	NULL
x	NULL
enhancer	NULL
[	NULL
34	NULL
]	NULL
)	NULL
in	NULL
front	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
in	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
both	NULL
mitogen	NULL
stimulation	NULL
and	NULL
Tax	NULL
resulted	NULL
in	NULL
a	NULL
substantial	NULL
increase	NULL
of	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
.	NULL

Further	NULL
4180	NULL
WESTENDORP	NULL
ET	NULL
AL	NULL
.	NULL

A	NULL
IL-2/CAT	NULL
ptat	NULL
ptax	NULL
1	NULL
t	NULL
U	NULL
0	NULL
10	NULL
20	NULL
30	NULL
%	NULL
transacetylation	NULL
B	NULL
B-actin/CAT	NULL
tat	NULL
CsA	NULL
L	NULL
I	NULL
U	NULL
I	NULL
0	NULL
10	NULL
20	NULL
30	NULL
%	NULL
transacetylation	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Comparison	NULL
of	NULL
the	NULL
CsA	NULL
sensitivities	NULL
of	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
HIV-1	NULL
Tat	NULL
and	NULL
HTLV-1	NULL
Tax	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
(	NULL
-	NULL
)	NULL
or	NULL
cotransfected	NULL
with	NULL
expression	NULL
vectors	NULL
for	NULL
fat	NULL
(	NULL
ptat	NULL
)	NULL
or	NULL
fax	NULL
(	NULL
ptax	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

MMB	NULL
,	NULL
no	NULL
CsA	NULL
added	NULL
;	NULL
D	NULL
,	NULL
CsA	NULL
added	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
of	NULL
CsA	NULL
treatment	NULL
and	NULL
cotransfection	NULL
with	NULL
ptat	NULL
(	NULL
tat	NULL
)	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
B-actin	NULL
promoter	NULL
in	NULL
pB-actin/CAT	NULL
.	NULL

Cells	NULL
were	NULL
mitogen	NULL
(	NULL
PHA	NULL
and	NULL
PMA	NULL
)	NULL
stimulated	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
and	NULL
treated	NULL
with	NULL
100	NULL
ng	NULL
of	NULL
CsA	NULL
per	NULL
ml	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
promoter	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
percent	NULL
transacetylation	NULL
.	NULL

The	NULL
average	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
error	NULL
bars	NULL
)	NULL
for	NULL
three	NULL
independent	NULL
transfections	NULL
are	NULL
shown	NULL
.	NULL

-	NULL
,	NULL
cells	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
alone	NULL
.	NULL

more	NULL
,	NULL
a	NULL
combination	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
and	NULL
Tax	NULL
had	NULL
a	NULL
much	NULL
stronger	NULL
effect	NULL
on	NULL
activity	NULL
than	NULL
Tax	NULL
or	NULL
mitogen	NULL
stimulation	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
no	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
NF-kB	NULL
activity	NULL
was	NULL
detected	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tat	NULL
requires	NULL
mitogen	NULL
stimulation	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
stimulated	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
to	NULL
investigate	NULL
the	NULL
possibility	NULL
of	NULL
synergistic	NULL
effects	NULL
of	NULL
mitogen	NULL
stimulation	NULL
and	NULL
Tat	NULL
(	NULL
or	NULL
Tax	NULL
)	NULL
on	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
Tat	NULL
did	NULL
not	NULL
synergize	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
to	NULL
increase	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
.	NULL

The	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
sequences	NULL
in	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
light-chain	NULL
enhancer	NULL
and	NULL
the	NULL
IL-2	NULL
enhancer	NULL
differ	NULL
slightly	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
tested	NULL
a	NULL
reporter	NULL
gene	NULL
construct	NULL
carrying	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NF-kB	NULL
motif	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Again	NULL
,	NULL
no	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
was	NULL
observed	NULL
in	NULL
unstimulated	NULL
and	NULL
PHA-PMA-stimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

To	NULL
validate	NULL
these	NULL
results	NULL
in	NULL
the	NULL
context	NULL
of	NULL
the	NULL
intact	NULL
IL-2	NULL
promoter	NULL
,	NULL
we	NULL
generated	NULL
an	NULL
NF-kB	NULL
point	NULL
mutation	NULL
shown	NULL
previously	NULL
to	NULL
abolish	NULL
NF-kB	NULL
binding	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
wild	NULL
type	NULL
J.	NULL
ViroL	NULL
.	NULL

and	NULL
the	NULL
mutated	NULL
IL-2	NULL
promoter	NULL
construct	NULL
were	NULL
tested	NULL
with	NULL
PHA-PMA-stimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
cotransfected	NULL
with	NULL
ptat	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
upper	NULL
two	NULL
bars	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
mutation	NULL
abolished	NULL
the	NULL
ability	NULL
of	NULL
HIV-1	NULL
Tat	NULL
to	NULL
transactivate	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
NF-KB	NULL
site	NULL
at	NULL
positions	NULL
-206	NULL
to	NULL
-195	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
necessary	NULL
but-as	NULL
judged	NULL
from	NULL
the	NULL
multimerized	NULL
NF-KB	NULL
reporter	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
-not	NULL
sufficient	NULL
for	NULL
transactivation	NULL
by	NULL
HIV-1	NULL
Tat	NULL
.	NULL

Apart	NULL
from	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
motif	NULL
,	NULL
the	NULL
IL-2	NULL
promoter	NULL
contains	NULL
various	NULL
sites	NULL
that	NULL
bind	NULL
proteins	NULL
believed	NULL
to	NULL
contribute	NULL
to	NULL
transcriptional	NULL
control	NULL
,	NULL
including	NULL
those	NULL
for	NULL
NF-AT	NULL
,	NULL
AP-1	NULL
,	NULL
Oct-1/2	NULL
,	NULL
CD28RC	NULL
,	NULL
and	NULL
others	NULL
(	NULL
20	NULL
,	NULL
48	NULL
)	NULL
.	NULL

These	NULL
sites	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
have	NULL
previously	NULL
been	NULL
grouped	NULL
into	NULL
five	NULL
functional	NULL
boxes	NULL
(	NULL
48	NULL
)	NULL
.	NULL

On	NULL
the	NULL
basis	NULL
of	NULL
this	NULL
division	NULL
,	NULL
we	NULL
constructed	NULL
a	NULL
series	NULL
of	NULL
5Â°	NULL
deletion	NULL
mutants	NULL
and	NULL
cloned	NULL
them	NULL
into	NULL
pBLCAT3	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
Tat	NULL
to	NULL
transactivate	NULL
the	NULL
truncated	NULL
promoter	NULL
constructs	NULL
was	NULL
tested	NULL
by	NULL
transient	NULL
cotransfection	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
as	NULL
described	NULL
above	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
deletion	NULL
of	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
to	NULL
position	NULL
-208	NULL
did	NULL
not	NULL
affect	NULL
Tat	NULL
transactivation	NULL
,	NULL
though	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
was	NULL
reduced	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
legend	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
neither	NULL
the	NULL
previously	NULL
described	NULL
NF-AT	NULL
site	NULL
(	NULL
positions	NULL
-286	NULL
to	NULL
-257	NULL
)	NULL
,	NULL
the	NULL
Oct-1/2	NULL
site	NULL
(	NULL
positions	NULL
-256	NULL
to	NULL
-242	NULL
)	NULL
,	NULL
nor	NULL
any	NULL
potential	NULL
unknown	NULL
binding	NULL
motif	NULL
upstream	NULL
of	NULL
position	NULL
-208	NULL
is	NULL
required	NULL
for	NULL
Tat	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
further	NULL
deletion	NULL
of	NULL
the	NULL
sequence	NULL
between	NULL
positions	NULL
~208	NULL
and	NULL
-158	NULL
abolished	NULL
most	NULL
of	NULL
the	NULL
Tat	NULL
transactivation	NULL
.	NULL

This	NULL
part	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
contains	NULL
the	NULL
AP-1	NULL
distal	NULL
site	NULL
(	NULL
positions	NULL
-185	NULL
to	NULL
-177	NULL
)	NULL
and	NULL
the	NULL
NF-KB	NULL
site	NULL
discussed	NULL
above	NULL
.	NULL

The	NULL
results	NULL
confirm	NULL
the	NULL
data	NULL
obtained	NULL
from	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
point	NULL
mutation	NULL
(	NULL
see	NULL
above	NULL
)	NULL
and	NULL
the	NULL
important	NULL
role	NULL
of	NULL
the	NULL
NF-kB	NULL
motif	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tat	NULL
.	NULL

Further	NULL
5	NULL
'	NULL
deletion	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
resulted	NULL
in	NULL
loss	NULL
of	NULL
the	NULL
residual	NULL
Tat	NULL
responsiveness	NULL
.	NULL

However	NULL
,	NULL
this	NULL
effect	NULL
was	NULL
only	NULL
marginally	NULL
significant	NULL
and	NULL
transacetylation	NULL
rates	NULL
obtained	NULL
with	NULL
the	NULL
respective	NULL
constructs	NULL
were	NULL
close	NULL
to	NULL
background	NULL
levels	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
the	NULL
sequence	NULL
between	NULL
positions	NULL
-208	NULL
and	NULL
+51	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
sufficient	NULL
for	NULL
transactivation	NULL
by	NULL
Tat	NULL
and	NULL
the	NULL
NF-kB	NULL
motif	NULL
is	NULL
a	NULL
key	NULL
element	NULL
in	NULL
this	NULL
sequence	NULL
.	NULL

Effect	NULL
of	NULL
exogenous	NULL
Tat	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Tat	NULL
secreted	NULL
by	NULL
one	NULL
cell	NULL
might	NULL
be	NULL
taken	NULL
up	NULL
by	NULL
neighboring	NULL
cells	NULL
and	NULL
exert	NULL
its	NULL
effect	NULL
on	NULL
IL-2	NULL
promoter	NULL
activity	NULL
of	NULL
the	NULL
latter	NULL
cells	NULL
.	NULL

Such	NULL
mechanisms	NULL
might	NULL
be	NULL
of	NULL
particular	NULL
importance	NULL
in	NULL
situations	NULL
where	NULL
infected	NULL
Tat-producing	NULL
T	NULL
cells	NULL
come	NULL
into	NULL
close	NULL
contact	NULL
with	NULL
uninfected	NULL
T	NULL
cells	NULL
,	NULL
e.g	NULL
.	NULL

,	NULL
in	NULL
lymphoid	NULL
tissue	NULL
of	NULL
HIV-1-infected	NULL
individuals	NULL
.	NULL

To	NULL
test	NULL
this	NULL
hypothesis	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
HeLa	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
tat	NULL
(	NULL
HeLa-tat	NULL
)	NULL
on	NULL
pIL-2/CAT-transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
cocultures	NULL
.	NULL

The	NULL
presence	NULL
of	NULL
native	NULL
,	NULL
biologically	NULL
active	NULL
Tat	NULL
in	NULL
the	NULL
HeLa-tat	NULL
cells	NULL
and	NULL
their	NULL
supernatant	NULL
was	NULL
demonstrated	NULL
by	NULL
transactivation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
after	NULL
transfection	NULL
of	NULL
the	NULL
HeLa	NULL
cells	NULL
with	NULL
pLTR/	NULL
CAT	NULL
or	NULL
coculture	NULL
with	NULL
Jurkat	NULL
T	NULL
cells	NULL
transfected	NULL
with	NULL
pLTR/	NULL
CAT	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
transactivation	NULL
level	NULL
of	NULL
pLTR/	NULL
CAT	NULL
was	NULL
generally	NULL
much	NULL
lower	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
might	NULL
reflect	NULL
a	NULL
better	NULL
uptake	NULL
of	NULL
Tat	NULL
into	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
an	NULL
enhancing	NULL
effect	NULL
of	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
on	NULL
the	NULL
Tat-induced	NULL
activity	NULL
of	NULL
LTR-driven	NULL
CAT	NULL
vector	NULL
constructs	NULL
has	NULL
previously	NULL
been	NULL
described	NULL
for	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
54	NULL
,	NULL
58	NULL
)	NULL
.	NULL

The	NULL
observed	NULL
transcellular	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
might	NULL
be	NULL
either	NULL
directly	NULL
mediated	NULL
by	NULL
Tat	NULL
or	NULL
indirectly	NULL
mediated	NULL
via	NULL
a	NULL
cytokine	NULL
secreted	NULL
from	NULL
HeLa-tat	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
used	NULL
rabbit	NULL
serum	NULL
raised	NULL
against	NULL
synthetic	NULL
HIV-1	NULL
Tat	NULL
to	NULL
neutralize	NULL
Tat	NULL
activity	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
HeLa-tat	NULL
cells	NULL
.	NULL

Normal	NULL
rabbit	NULL
serum	NULL
was	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
pretreatment	NULL
of	NULL
HeLa-tat	NULL
cell	NULL
supernatant	NULL
with	NULL
anti-Tat	NULL
se	NULL
VoL	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
A	NULL
4xNF-kB/CAT	NULL
(	NULL
Iigk	NULL
)	NULL
35	NULL
30	NULL
-25-	NULL
3	NULL
*~	NULL
Â®	NULL
3	NULL
E	NULL
i-x	NULL
10	NULL
-5-	NULL
=o	NULL
-	NULL
o	NULL
$	NULL
04	NULL
0-	NULL
+	NULL
#	NULL
ptat	NULL
=o	NULL
o	NULL
c-	NULL
#	NULL
00	NULL
-	NULL
o-ptax	NULL
<	NULL
0	NULL
e	NULL
e	NULL
-	NULL
4	NULL
0+	NULL
HIV-1	NULL
Tat	NULL
UPREGULATES	NULL
IL-2	NULL
EXPRESSION	NULL
4181	NULL
B	NULL
4xNF-KB/CAT	NULL
(	NULL
IL-2P	NULL
)	NULL
35	NULL
30	NULL
7	NULL
15	NULL
%	NULL
Transacetylation	NULL
10	NULL
PHA/PMA	NULL
-=	NULL
+	NULL
+	NULL
ptat	NULL
-o	NULL
o	NULL
$	NULL
oc-	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Effect	NULL
of	NULL
HIV-1	NULL
Tat	NULL
and	NULL
HTLV-I	NULL
Tax	NULL
on	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
were	NULL
transiently	NULL
cotransfected	NULL
with	NULL
a	NULL
reporter	NULL
gene	NULL
construct	NULL
carrying	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
sequence	NULL
(	NULL
4XNF-	NULL
Â«	NULL
B	NULL
)	NULL
from	NULL
the	NULL
immunoglobulin	NULL
kappa	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
Igk	NULL
)	NULL
(	NULL
A	NULL
)	NULL
or	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
IL-2P	NULL
)	NULL
(	NULL
B	NULL
)	NULL
in	NULL
front	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
and	NULL
expression	NULL
vectors	NULL
for	NULL
tat	NULL
(	NULL
ptat	NULL
)	NULL
or	NULL
tax	NULL
(	NULL
ptax	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Cells	NULL
were	NULL
mitogen	NULL
(	NULL
PHA	NULL
and	NULL
PMA	NULL
)	NULL
stimulated	NULL
as	NULL
shown	NULL
.	NULL

The	NULL
NF-	NULL
Â«	NULL
B	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
percent	NULL
transacetylation	NULL
.	NULL

Values	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
;	NULL
variation	NULL
was	NULL
less	NULL
than	NULL
18	NULL
%	NULL
.	NULL

+	NULL
,	NULL
present	NULL
;	NULL
-	NULL
,	NULL
absent	NULL
.	NULL

rum	NULL
,	NULL
but	NULL
not	NULL
with	NULL
normal	NULL
rabbit	NULL
serum	NULL
,	NULL
blocked	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

This	NULL
blocking	NULL
effect	NULL
was	NULL
concentration	NULL
dependent	NULL
and	NULL
was	NULL
no	NULL
longer	NULL
observed	NULL
with	NULL
high	NULL
dilutions	NULL
of	NULL
anti-Tat	NULL
serum	NULL
.	NULL

The	NULL
results	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

7B	NULL
and	NULL
C	NULL
and	NULL
Fig	NULL
.	NULL

8	NULL
demonstrate	NULL
the	NULL
increase	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
exogenous	NULL
Tat	NULL
.	NULL

Both	NULL
HeLa-tat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
and	NULL
their	NULL
Tat-containing	NULL
supernatant	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
caused	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
in	NULL
PHA-PMA-stimulated	NULL
IL-2	NULL
promoter	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
demonstrate	NULL
that	NULL
HIV-1	NULL
Tat	NULL
may	NULL
regulate	NULL
expression	NULL
of	NULL
genes	NULL
in	NULL
noninfected	NULL
cells	NULL
.	NULL

Effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
on	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
.	NULL

An	NULL
artificial	NULL
IL-2	NULL
promoter-CAT	NULL
fusion	NULL
construct	NULL
differs	NULL
from	NULL
the	NULL
-256	NULL
-208	NULL
-158	NULL
Lommel	NULL
-93	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
fold	NULL
Tat-transactivation	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

Transactivation	NULL
of	NULL
5	NULL
'	NULL
deletion	NULL
mutants	NULL
(	NULL
the	NULL
position	NULL
of	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
truncated	NULL
promoter	NULL
sequences	NULL
is	NULL
indicated	NULL
;	NULL
in	NULL
all	NULL
mutants	NULL
,	NULL
the	NULL
3	NULL
'	NULL
end	NULL
was	NULL
at	NULL
position	NULL
+47	NULL
)	NULL
and	NULL
an	NULL
NF-	NULL
Â«	NULL
B	NULL
mutant	NULL
[	NULL
M	NULL
(	NULL
kB	NULL
)	NULL
]	NULL
with	NULL
mutations	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
HIV-1	NULL
Tat	NULL
.	NULL

The	NULL
fold	NULL
transactivation	NULL
of	NULL
the	NULL
promoter-CAT	NULL
constructs	NULL
by	NULL
cotransfection	NULL
with	NULL
ptat	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
average	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
error	NULL
bars	NULL
)	NULL
for	NULL
three	NULL
independent	NULL
transfections	NULL
are	NULL
shown	NULL
.	NULL

Fold	NULL
activation	NULL
and	NULL
average	NULL
transacetylation	NULL
rates	NULL
(	NULL
in	NULL
parentheses	NULL
)	NULL
after	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
-286	NULL
,	NULL
32	NULL
(	NULL
7.2	NULL
%	NULL
)	NULL
;	NULL
-256	NULL
,	NULL
12	NULL
(	NULL
3.4	NULL
%	NULL
)	NULL
,	NULL
-208	NULL
,	NULL
6	NULL
(	NULL
2.7	NULL
%	NULL
)	NULL
;	NULL
-157	NULL
,	NULL
2.5	NULL
(	NULL
1.3	NULL
%	NULL
)	NULL
;	NULL
-93	NULL
,	NULL
1.8	NULL
(	NULL
0.9	NULL
%	NULL
)	NULL
;	NULL
M	NULL
(	NULL
kB	NULL
)	NULL
,	NULL
17	NULL
(	NULL
4.4	NULL
%	NULL
)	NULL
.	NULL

pLTR/CAT	NULL
pIL-2/CAT	NULL
[	NULL
]	NULL
+SN	NULL
(	NULL
Hela	NULL
)	NULL
[	NULL
C	NULL
]	NULL
+SN	NULL
(	NULL
Hela	NULL
)	NULL
C	NULL
]	NULL
+Hela	NULL
EK	NULL
+3N	NULL
(	NULL
Hola	NULL
:	NULL
ta	NULL
)	NULL
BK	NULL
+N	NULL
(	NULL
Helatat	NULL
)	NULL
MRJ	NULL
+Helatat	NULL
107	NULL
10	NULL
-30-	NULL
9	NULL
8	NULL
Â»	NULL
]	NULL
Â§	NULL
â¬	NULL
a	NULL
s-	NULL
s-Â§	NULL
xt	NULL
10	NULL
-o-	NULL
o-	NULL
o-PHA/PMA	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
+	NULL
FIG	NULL
.	NULL

7	NULL
.	NULL

Upregulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
extracellular	NULL
Tat	NULL
.	NULL

(	NULL
A	NULL
)	NULL
HIV-1	NULL
LTR	NULL
promoter	NULL
activity	NULL
measured	NULL
as	NULL
CAT	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
pLTR/CAT	NULL
and	NULL
cultured	NULL
in	NULL
supernatant	NULL
of	NULL
HeLa-tat	NULL
or	NULL
HeLa	NULL
cells	NULL
as	NULL
a	NULL
control	NULL
.	NULL

(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
IL-2	NULL
promoter	NULL
activity	NULL
measured	NULL
as	NULL
CAT	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
and	NULL
cocultured	NULL
with	NULL
a	NULL
HeLa	NULL
cell	NULL
line	NULL
stably	NULL
transfected	NULL
with	NULL
tat	NULL
(	NULL
Hela-tat	NULL
)	NULL
or	NULL
the	NULL
wild-type	NULL
HeLa	NULL
cell	NULL
line	NULL
(	NULL
Hela	NULL
)	NULL
(	NULL
C	NULL
)	NULL
or	NULL
cultured	NULL
in	NULL
supernatants	NULL
(	NULL
SN	NULL
)	NULL
of	NULL
the	NULL
latter	NULL
cells	NULL
(	NULL
B	NULL
)	NULL
.	NULL

Values	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
transfections	NULL
;	NULL
variation	NULL
was	NULL
less	NULL
than	NULL
16	NULL
%	NULL
.	NULL

The	NULL
supernatants	NULL
of	NULL
HeLa-tat	NULL
and	NULL
wild-type	NULL
HeLa	NULL
cells	NULL
did	NULL
not	NULL
influence	NULL
proliferation	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
mitogens	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

+	NULL
,	NULL
present	NULL
;	NULL
-	NULL
,	NULL
absent	NULL
.	NULL

4182	NULL
WESTENDORP	NULL
ET	NULL
AL	NULL
.	NULL

-	NULL
Tat	NULL
+	NULL
Tat	NULL
+	NULL
Tat	NULL
+	NULL
anti-Tat	NULL
(	NULL
1:500	NULL
)	NULL
+	NULL
Tat	NULL
+	NULL
anti-Tat	NULL
(	NULL
1:20.000	NULL
)	NULL
+	NULL
Tat	NULL
+	NULL
NRS	NULL
T	NULL
0	NULL
5	NULL
10	NULL
15	NULL
%	NULL
transacetylation	NULL
FIG	NULL
.	NULL

8	NULL
.	NULL

Blocking	NULL
of	NULL
the	NULL
effect	NULL
of	NULL
extracellular	NULL
Tat	NULL
by	NULL
anti-Tat	NULL
serum	NULL
.	NULL

IL-2	NULL
promoter	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
CAT	NULL
activity	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
pIL-2/CAT	NULL
and	NULL
cultured	NULL
in	NULL
supernatant	NULL
of	NULL
HeLa-tat	NULL
(	NULL
+	NULL
Tat	NULL
)	NULL
or	NULL
HeLa	NULL
(	NULL
-	NULL
Tat	NULL
)	NULL
cells	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Cells	NULL
were	NULL
mitogen	NULL
(	NULL
PHA	NULL
and	NULL
PMA	NULL
)	NULL
stimulated	NULL
(	NULL
&	NULL
)	NULL
or	NULL
unstimulated	NULL
(	NULL
0	NULL
)	NULL
as	NULL
shown	NULL
.	NULL

anti-Tat	NULL
,	NULL
treatment	NULL
of	NULL
the	NULL
HeLa-tat	NULL
supernatant	NULL
with	NULL
anti-Tat	NULL
serum	NULL
,	NULL
diluted	NULL
1:500	NULL
or	NULL
1:20,000	NULL
;	NULL
NRS	NULL
,	NULL
normal	NULL
rabbit	NULL
serum	NULL
used	NULL
as	NULL
a	NULL
control	NULL
.	NULL

The	NULL
average	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
error	NULL
bars	NULL
)	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

endogenous	NULL
IL-2	NULL
gene	NULL
with	NULL
respect	NULL
to	NULL
the	NULL
flanking	NULL
DNA	NULL
sequences	NULL
,	NULL
the	NULL
RNA	NULL
transcript	NULL
,	NULL
and	NULL
possibly	NULL
the	NULL
chromatin	NULL
structure	NULL
.	NULL

This	NULL
difference	NULL
might	NULL
result	NULL
in	NULL
a	NULL
different	NULL
regulation	NULL
and	NULL
expression	NULL
pattern	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
also	NULL
tested	NULL
expression	NULL
of	NULL
the	NULL
endogenous	NULL
IL-2	NULL
gene	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
cultured	NULL
in	NULL
Tat-containing	NULL
supernatant	NULL
from	NULL
HeLa-tat	NULL
cells	NULL
Figure	NULL
9	NULL
shows	NULL
that	NULL
exposure	NULL
to	NULL
extracellular	NULL
,	NULL
native	NULL
Tat	NULL
resulted	NULL
in	NULL
an	NULL
approximately	NULL
twofold	NULL
increase	NULL
of	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
only	NULL
4	NULL
h	NULL
after	NULL
mitogen	NULL
stimulation	NULL
,	NULL
whereas	NULL
the	NULL
level	NULL
of	NULL
B-actin	NULL
mRNA	NULL
used	NULL
as	NULL
a	NULL
control	NULL
was	NULL
unaffected	NULL
.	NULL

IL-2	NULL
mRNA	NULL
levels	NULL
20	NULL
h	NULL
after	NULL
stimulation	NULL
were	NULL
comparable	NULL
in	NULL
the	NULL
absence	NULL
and	NULL
presence	NULL
of	NULL
Tat	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
effect	NULL
of	NULL
Tat	NULL
on	NULL
secretion	NULL
of	NULL
IL-2	NULL
could	NULL
also	NULL
be	NULL
observed	NULL
,	NULL
we	NULL
measured	NULL
IL-2	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
purified	NULL
peripheral	NULL
T	NULL
cells	NULL
cultured	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
exogenous	NULL
Tat	NULL
and	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
for	NULL
15	NULL
h.	NULL
Figure	NULL
10A	NULL
shows	NULL
that	NULL
IL-2	NULL
in	NULL
the	NULL
supernatant	NULL
of	NULL
Jurkat	NULL
T	NULL
cells	NULL
was	NULL
increased	NULL
more	NULL
than	NULL
twofold	NULL
when	NULL
Tat	NULL
was	NULL
present	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

Oh	NULL
Oh	NULL
4h	NULL
20h	NULL
4h	NULL
20h	NULL
B-actin	NULL
HT	NULL
H	NULL
HT	NULL
__	NULL
HT	NULL
H	NULL
H	NULL
FIG	NULL
.	NULL

9	NULL
.	NULL

Detection	NULL
of	NULL
IL-2	NULL
mRNA	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
Northern	NULL
blotting	NULL
of	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
*	NULL
mRNA	NULL
from	NULL
Jurkat	NULL
T	NULL
cells	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
in	NULL
Tat-containing	NULL
supernatant	NULL
of	NULL
HeLa-tat	NULL
cells	NULL
(	NULL
HT	NULL
)	NULL
or	NULL
of	NULL
wild-type	NULL
HeLa	NULL
cells	NULL
(	NULL
H	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
was	NULL
performed	NULL
by	NULL
using	NULL
probes	NULL
specific	NULL
for	NULL
IL-2	NULL
or	NULL
B-actin	NULL
as	NULL
a	NULL
control	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

The	NULL
average	NULL
fold	NULL
induction	NULL
(	NULL
+	NULL
standard	NULL
deviation	NULL
)	NULL
of	NULL
IL-2	NULL
mRNA	NULL
by	NULL
Tat	NULL
as	NULL
measured	NULL
by	NULL
densitometry	NULL
was	NULL
2.16	NULL
(	NULL
+	NULL
0.44	NULL
)	NULL
at	NULL
4	NULL
h	NULL
and	NULL
1.18	NULL
(	NULL
+	NULL
0.37	NULL
)	NULL
at	NULL
20	NULL
h.	NULL
J.	NULL
ViroL	NULL
.	NULL

5	NULL
15	NULL
4-	NULL
T	NULL
v	NULL
107	NULL
=	NULL
37	NULL
E	NULL
&	NULL
Â£	NULL
cu	NULL
3	NULL
``	NULL
,	NULL
5-1	NULL
at	NULL
,	NULL
10	NULL
-~	NULL
like	NULL
Jurkat	NULL
+	NULL
H	NULL
Jurkat	NULL
+	NULL
HT	NULL
T-cells	NULL
+	NULL
H	NULL
T-cells	NULL
+	NULL
HT	NULL
FIG	NULL
.	NULL

10	NULL
.	NULL

Upregulation	NULL
of	NULL
IL-2	NULL
secretion	NULL
from	NULL
activated	NULL
Jurkat	NULL
(	NULL
A	NULL
)	NULL
and	NULL
peripheral	NULL
(	NULL
B	NULL
)	NULL
T	NULL
cells	NULL
by	NULL
exogenous	NULL
Tat	NULL
.	NULL

Jurkat	NULL
T	NULL
cells	NULL
or	NULL
purified	NULL
peripheral	NULL
T	NULL
cells	NULL
were	NULL
cultured	NULL
for	NULL
12	NULL
h	NULL
in	NULL
Tat-containing	NULL
supernatant	NULL
of	NULL
HeLa-tat	NULL
cells	NULL
(	NULL
HT	NULL
)	NULL
or	NULL
supernatant	NULL
of	NULL
wild-type	NULL
HeLa	NULL
cells	NULL
(	NULL
H	NULL
)	NULL
as	NULL
a	NULL
control	NULL
.	NULL

IL-2	NULL
secretion	NULL
was	NULL
measured	NULL
15	NULL
h	NULL
after	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
by	NULL
using	NULL
an	NULL
IL-2	NULL
ELISA	NULL
.	NULL

The	NULL
average	NULL
values	NULL
and	NULL
standard	NULL
deviations	NULL
(	NULL
error	NULL
bars	NULL
)	NULL
for	NULL
three	NULL
independent	NULL
experiments	NULL
are	NULL
shown	NULL
.	NULL

Normal	NULL
T	NULL
cells	NULL
and	NULL
malignant	NULL
Jurkat	NULL
T	NULL
cells	NULL
differ	NULL
in	NULL
growth	NULL
control	NULL
and	NULL
requirements	NULL
for	NULL
growth	NULL
factors	NULL
like	NULL
IL-2	NULL
and	NULL
IL-4	NULL
.	NULL

Therefore	NULL
,	NULL
we	NULL
tested	NULL
whether	NULL
Tat	NULL
also	NULL
influences	NULL
IL-2	NULL
secretion	NULL
from	NULL
activated	NULL
normal	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

Figure	NULL
10B	NULL
demonstrates	NULL
the	NULL
same	NULL
significant	NULL
enhancement	NULL
of	NULL
IL-2	NULL
secretion	NULL
by	NULL
Tat	NULL
in	NULL
activated	NULL
normal	NULL
peripheral	NULL
T	NULL
cells	NULL
as	NULL
observed	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

DISCUSSION	NULL
The	NULL
data	NULL
presented	NULL
in	NULL
this	NULL
paper	NULL
show	NULL
that	NULL
HIV-1	NULL
Tat	NULL
upregulates	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
IL-2	NULL
secretion	NULL
in	NULL
activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
and	NULL
in	NULL
freshly	NULL
isolated	NULL
activated	NULL
peripheral	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
effects	NULL
of	NULL
Tat	NULL
on	NULL
promoter	NULL
activity	NULL
,	NULL
mRNA	NULL
expression	NULL
,	NULL
and	NULL
IL-2	NULL
secretion	NULL
suggested	NULL
that	NULL
IL-2	NULL
upregulation	NULL
was	NULL
primarily	NULL
caused	NULL
at	NULL
the	NULL
transcriptional	NULL
level	NULL
.	NULL

Our	NULL
experiments	NULL
addressed	NULL
the	NULL
short-term	NULL
effects	NULL
of	NULL
HIV-1	NULL
Tat	NULL
on	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
long-term	NULL
effects	NULL
of	NULL
Tat	NULL
on	NULL
T	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
might	NULL
be	NULL
different	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
accordance	NULL
with	NULL
previous	NULL
observations	NULL
(	NULL
43	NULL
)	NULL
,	NULL
we	NULL
also	NULL
found	NULL
decreased	NULL
IL-2	NULL
expression	NULL
in	NULL
stable	NULL
fat-transfected	NULL
mitogen-activated	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
prolonged	NULL
high-level	NULL
expression	NULL
of	NULL
Tat	NULL
in	NULL
T	NULL
cells	NULL
might	NULL
result	NULL
in	NULL
suppression	NULL
rather	NULL
than	NULL
stimulation	NULL
of	NULL
IL-2	NULL
expression	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
Tat	NULL
might	NULL
depend	NULL
on	NULL
the	NULL
duration	NULL
of	NULL
exposure	NULL
of	NULL
T	NULL
cells	NULL
to	NULL
Tat	NULL
.	NULL

Upregulation	NULL
of	NULL
IL-2	NULL
expression	NULL
might	NULL
therefore	NULL
only	NULL
be	NULL
transient	NULL
in	NULL
stable	NULL
Tat	NULL
transfectants	NULL
or	NULL
in	NULL
T	NULL
cells	NULL
of	NULL
HIV-1-infected	NULL
individuals	NULL
.	NULL

This	NULL
assumption	NULL
is	NULL
supported	NULL
by	NULL
our	NULL
observation	NULL
that	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
were	NULL
strongly	NULL
increased	NULL
by	NULL
Tat	NULL
4	NULL
h	NULL
after	NULL
mitogen	NULL
stimulation	NULL
and	NULL
reached	NULL
normal	NULL
levels	NULL
16	NULL
h	NULL
later	NULL
.	NULL

The	NULL
differential	NULL
effects	NULL
of	NULL
Tat	NULL
on	NULL
IL-2	NULL
secretion	NULL
of	NULL
T	NULL
cells	NULL
,	NULL
upregulation	NULL
upon	NULL
short-term	NULL
exposure	NULL
and	NULL
downregulation	NULL
upon	NULL
long-term	NULL
Vor	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
exposure	NULL
,	NULL
might	NULL
also	NULL
make	NULL
detection	NULL
of	NULL
IL-2	NULL
levels	NULL
in	NULL
serum	NULL
of	NULL
HIV-1-infected	NULL
individuals	NULL
difficult	NULL
(	NULL
6	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
the	NULL
Tat	NULL
effect	NULL
on	NULL
IL-2	NULL
expression	NULL
remains	NULL
partly	NULL
unclear	NULL
.	NULL

Sequence	NULL
comparison	NULL
of	NULL
the	NULL
IL-2	NULL
RNA	NULL
and	NULL
TAR	NULL
,	NULL
the	NULL
Tat-binding	NULL
site	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
RNA	NULL
,	NULL
revealed	NULL
no	NULL
binding	NULL
site	NULL
for	NULL
Tat	NULL
on	NULL
IL-2	NULL
RNA	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
presence	NULL
of	NULL
stem-loop	NULL
structures	NULL
containing	NULL
the	NULL
CUGGGA	NULL
sequence	NULL
downstream	NULL
of	NULL
the	NULL
transcriptional	NULL
start	NULL
site	NULL
of	NULL
the	NULL
TNF-B	NULL
promoter	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
play	NULL
a	NULL
role	NULL
in	NULL
Tat-induced	NULL
TNF-B	NULL
activation	NULL
(	NULL
4	NULL
)	NULL
.	NULL

Similar	NULL
sequences	NULL
forming	NULL
TAR-like	NULL
stem-loops	NULL
have	NULL
been	NULL
identified	NULL
downstream	NULL
of	NULL
the	NULL
RNA	NULL
initiation	NULL
site	NULL
of	NULL
the	NULL
JC	NULL
virus	NULL
promoter	NULL
(	NULL
5	NULL
,	NULL
44	NULL
)	NULL
.	NULL

However	NULL
,	NULL
no	NULL
such	NULL
sequences	NULL
are	NULL
present	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
IL-2	NULL
RNA	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
transactivation	NULL
of	NULL
IL-2	NULL
expression	NULL
by	NULL
Tat	NULL
represents	NULL
a	NULL
new	NULL
TAR-independent	NULL
mechanism	NULL
of	NULL
transcriptional	NULL
activation	NULL
.	NULL

However	NULL
,	NULL
the	NULL
binding	NULL
of	NULL
Tat	NULL
to	NULL
a	NULL
stem-loop	NULL
structure	NULL
,	NULL
homologous	NULL
to	NULL
but	NULL
distinct	NULL
from	NULL
TAR	NULL
,	NULL
at	NULL
the	NULL
5	NULL
end	NULL
of	NULL
IL-2	NULL
RNA	NULL
which	NULL
might-as	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR-tether	NULL
Tat	NULL
to	NULL
the	NULL
promoter	NULL
can	NULL
not	NULL
completely	NULL
be	NULL
ruled	NULL
out	NULL
.	NULL

Comparison	NULL
of	NULL
HIV-1	NULL
Tat	NULL
and	NULL
the	NULL
transactivator	NULL
of	NULL
a	NULL
related	NULL
human	NULL
retrovirus	NULL
,	NULL
HTLV-I	NULL
Tax	NULL
,	NULL
also	NULL
known	NULL
to	NULL
synergize	NULL
with	NULL
mitogens	NULL
to	NULL
stimulate	NULL
IL-2	NULL
expression	NULL
(	NULL
53	NULL
)	NULL
,	NULL
revealed	NULL
clear	NULL
differences	NULL
but	NULL
also	NULL
similarities	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
Tat	NULL
was	NULL
completely	NULL
blocked	NULL
with	NULL
relatively	NULL
low	NULL
concentrations	NULL
of	NULL
the	NULL
immunosuppressant	NULL
CsA	NULL
.	NULL

Tax	NULL
,	NULL
however	NULL
,	NULL
was	NULL
shown	NULL
to	NULL
circumvent	NULL
the	NULL
effects	NULL
of	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
(	NULL
51	NULL
,	NULL
53	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
Tax	NULL
,	NULL
but	NULL
not	NULL
Tat	NULL
,	NULL
could	NULL
transactivate	NULL
a	NULL
multimerized	NULL
NF-kB	NULL
binding	NULL
motif	NULL
.	NULL

However	NULL
,	NULL
both	NULL
transacti-vators	NULL
synergized	NULL
with	NULL
PHA	NULL
and	NULL
PMA	NULL
stimulation	NULL
of	NULL
cells	NULL
in	NULL
transactivation	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

Though	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
binding	NULL
sequence	NULL
was	NULL
not	NULL
sufficient	NULL
for	NULL
transactivation	NULL
by	NULL
Tat	NULL
,	NULL
it	NULL
was	NULL
still	NULL
required	NULL
to	NULL
confer	NULL
Tat	NULL
responsiveness	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
enhancer	NULL
element	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
,	NULL
composed	NULL
of	NULL
two	NULL
NF-kB	NULL
motifs	NULL
(	NULL
3	NULL
)	NULL
,	NULL
and	NULL
Tat	NULL
are	NULL
required	NULL
for	NULL
TAR-independent	NULL
activation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
in	NULL
PMA-treated	NULL
Jurkat	NULL
T	NULL
cells	NULL
(	NULL
24	NULL
)	NULL
and	NULL
glial	NULL
cells	NULL
(	NULL
57	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
Tat	NULL
may	NULL
be	NULL
capable	NULL
of	NULL
interacting	NULL
directly	NULL
with	NULL
certain	NULL
Â«	NULL
kB	NULL
binding	NULL
proteins	NULL
present	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
glial	NULL
cells	NULL
and	NULL
can	NULL
associate	NULL
with	NULL
promoters	NULL
independently	NULL
of	NULL
TAR	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Tat	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
probably	NULL
an	NULL
important	NULL
example	NULL
of	NULL
such	NULL
a	NULL
mechanism	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
involvement	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
xB	NULL
element	NULL
and	NULL
at	NULL
least	NULL
one	NULL
additional	NULL
element	NULL
downstream	NULL
of	NULL
position	NULL
-208	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
in	NULL
transactivation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
Tat	NULL
.	NULL

Possible	NULL
elements	NULL
downstream	NULL
of	NULL
this	NULL
position	NULL
include	NULL
NF-AT	NULL
,	NULL
AP-1	NULL
,	NULL
OAP	NULL
,	NULL
Oct-1/2	NULL
,	NULL
and	NULL
CD28RC	NULL
.	NULL

Of	NULL
these	NULL
,	NULL
NF-AT-1	NULL
,	NULL
AP-1	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
OAP	NULL
(	NULL
59	NULL
)	NULL
have	NULL
been	NULL
described	NULL
to	NULL
be	NULL
CsA	NULL
sensitive	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
these	NULL
elements	NULL
would	NULL
provide	NULL
an	NULL
explanation	NULL
for	NULL
blocking	NULL
of	NULL
the	NULL
Tat	NULL
but	NULL
not	NULL
the	NULL
Tax	NULL
effect	NULL
by	NULL
the	NULL
immunosuppressant	NULL
.	NULL

Further	NULL
mutational	NULL
analysis	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
necessary	NULL
to	NULL
identify	NULL
additional	NULL
requirements	NULL
of	NULL
Tat	NULL
transactivation	NULL
and	NULL
elements	NULL
interacting	NULL
with	NULL
Tat	NULL
.	NULL

Thus	NULL
,	NULL
an	NULL
influence	NULL
of	NULL
Tat	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
specific	NULL
transcription	NULL
factors	NULL
or	NULL
regulatory	NULL
elements	NULL
has	NULL
recently	NULL
been	NULL
described	NULL
for	NULL
the	NULL
murine	NULL
cytomegalovirus	NULL
major	NULL
immediate-early	NULL
promoter	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
a	NULL
direct	NULL
(	NULL
27	NULL
)	NULL
and	NULL
functional	NULL
(	NULL
30	NULL
)	NULL
interaction	NULL
of	NULL
Tat	NULL
and	NULL
the	NULL
transcription	NULL
factor	NULL
Spl	NULL
has	NULL
been	NULL
demonstrated	NULL
for	NULL
the	NULL
HIV-1	NULL
LTR	NULL
.	NULL

Intracellular	NULL
expression	NULL
of	NULL
Tat	NULL
in	NULL
transfected	NULL
Jurkat	NULL
T	NULL
cells	NULL
may	NULL
not	NULL
correctly	NULL
represent	NULL
the	NULL
pathological	NULL
situation	NULL
for	NULL
AIDS	NULL
.	NULL

Consequently	NULL
,	NULL
its	NULL
biological	NULL
significance	NULL
may	NULL
be	NULL
difficult	NULL
to	NULL
interpret	NULL
.	NULL

Therefore	NULL
,	NULL
it	NULL
is	NULL
particularly	NULL
significant	NULL
that	NULL
the	NULL
results	NULL
presented	NULL
here	NULL
are	NULL
not	NULL
restricted	NULL
to	NULL
intracellular	NULL
Tat	NULL
.	NULL

Extracellular	NULL
Tat	NULL
,	NULL
secreted	NULL
by	NULL
Tat-producing	NULL
cells	NULL
,	NULL
was	NULL
taken	NULL
up	NULL
by	NULL
neighboring	NULL
T	NULL
cells	NULL
and	NULL
transactivated	NULL
IL-2	NULL
expression	NULL
after	NULL
mitogen	NULL
stimulation	NULL
.	NULL

This	NULL
effect	NULL
could	NULL
specifically	NULL
be	NULL
blocked	NULL
with	NULL
anti-Tat	NULL
antibodies	NULL
.	NULL

In	NULL
our	NULL
experiments	NULL
,	NULL
endog-	NULL
HIV-1	NULL
Tat	NULL
UPREGULATES	NULL
IL-2	NULL
EXPRESSION	NULL
4183	NULL
enous	NULL
Tat	NULL
evoked	NULL
a	NULL
much	NULL
stronger	NULL
increase	NULL
in	NULL
IL-2	NULL
promoter	NULL
activity	NULL
than	NULL
did	NULL
exogenous	NULL
Tat	NULL
(	NULL
a	NULL
five-	NULL
to	NULL
eightfold	NULL
versus	NULL
a	NULL
two-	NULL
to	NULL
threefold	NULL
increase	NULL
)	NULL
.	NULL

This	NULL
difference	NULL
is	NULL
most	NULL
likely	NULL
explained	NULL
by	NULL
a	NULL
lower	NULL
concentration	NULL
of	NULL
secreted	NULL
(	NULL
exogenous	NULL
)	NULL
Tat	NULL
in	NULL
the	NULL
culture	NULL
medium	NULL
.	NULL

Thus	NULL
,	NULL
exposure	NULL
of	NULL
cells	NULL
to	NULL
exogenous	NULL
Tat	NULL
may	NULL
yield	NULL
lower	NULL
intracellular	NULL
concentrations	NULL
of	NULL
Tat	NULL
than	NULL
does	NULL
Tat	NULL
expression	NULL
within	NULL
the	NULL
cell	NULL
.	NULL

In	NULL
accordance	NULL
,	NULL
concentration	NULL
dependence	NULL
of	NULL
Tat	NULL
effects	NULL
has	NULL
recently	NULL
been	NULL
demonstrated	NULL
for	NULL
purified	NULL
recombinant	NULL
Tat	NULL
(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
vivo	NULL
,	NULL
Tat	NULL
may	NULL
be	NULL
concentrated	NULL
in	NULL
lymphoid	NULL
tissue	NULL
at	NULL
sites	NULL
where	NULL
HIV-1	NULL
replication	NULL
is	NULL
most	NULL
active	NULL
during	NULL
the	NULL
clinically	NULL
latent	NULL
period	NULL
of	NULL
HIV-1	NULL
infection	NULL
(	NULL
13	NULL
,	NULL
42	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
close	NULL
contact	NULL
of	NULL
cells	NULL
at	NULL
such	NULL
sites	NULL
might	NULL
make	NULL
uptake	NULL
of	NULL
Tat	NULL
by	NULL
surrounding	NULL
noninfected	NULL
T	NULL
cells	NULL
particularly	NULL
efficient	NULL
.	NULL

This	NULL
effect	NULL
may	NULL
therefore	NULL
exceed	NULL
the	NULL
effect	NULL
observed	NULL
with	NULL
our	NULL
cell	NULL
cultures	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
Tat	NULL
produced	NULL
and	NULL
secreted	NULL
by	NULL
infected	NULL
lymphocytes	NULL
or	NULL
macrophages	NULL
in	NULL
the	NULL
lymphoid	NULL
tissue	NULL
is	NULL
taken	NULL
up	NULL
by	NULL
surrounding	NULL
noninfected	NULL
T	NULL
cells	NULL
and	NULL
influences	NULL
their	NULL
IL-2	NULL
production	NULL
.	NULL

Ensuing	NULL
fluctuations	NULL
of	NULL
IL-2	NULL
levels	NULL
in	NULL
the	NULL
lymphoid	NULL
microenvironment	NULL
might	NULL
then	NULL
severely	NULL
influence	NULL
T-cell	NULL
function	NULL
in	NULL
HIV-1	NULL
infection	NULL
.	NULL

T-cell	NULL
activation	NULL
is	NULL
known	NULL
to	NULL
be	NULL
required	NULL
for	NULL
efficient	NULL
virus	NULL
propagation	NULL
.	NULL

Therefore	NULL
,	NULL
increased	NULL
IL-2	NULL
levels	NULL
might	NULL
enhance	NULL
viral	NULL
replication	NULL
and	NULL
virus	NULL
spread	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
increased	NULL
IL-2	NULL
levels	NULL
are	NULL
in	NULL
accordance	NULL
with	NULL
and	NULL
might	NULL
help	NULL
to	NULL
explain	NULL
the	NULL
high	NULL
frequency	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
and	NULL
follicular	NULL
hyperplasia	NULL
and	NULL
a	NULL
high	NULL
rate	NULL
of	NULL
viral	NULL
replication	NULL
observed	NULL
in	NULL
lymphoid	NULL
tissue	NULL
early	NULL
in	NULL
the	NULL
course	NULL
of	NULL
HIV-1	NULL
infection	NULL
(	NULL
42	NULL
)	NULL
.	NULL

HIV-1	NULL
Tat-mediated	NULL
dysregulation	NULL
of	NULL
IL-2	NULL
and	NULL
possibly	NULL
other	NULL
inflammatory	NULL
cytokines	NULL
(	NULL
4	NULL
)	NULL
might	NULL
contribute	NULL
to	NULL
the	NULL
apparent	NULL
immuno-logic	NULL
dysfunction	NULL
observed	NULL
in	NULL
AIDS	NULL
patients	NULL
,	NULL
or	NULL
to	NULL
the	NULL
development	NULL
of	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
(	NULL
14	NULL
,	NULL
15	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
an	NULL
increase	NULL
in	NULL
IL-2	NULL
levels	NULL
caused	NULL
by	NULL
Tat	NULL
might	NULL
be	NULL
a	NULL
factor	NULL
that	NULL
contributes	NULL
to	NULL
the	NULL
hypergammaglobulinemia	NULL
described	NULL
in	NULL
connection	NULL
with	NULL
AIDS	NULL
(	NULL
33	NULL
)	NULL
.	NULL

Further	NULL
studies	NULL
are	NULL
necessary	NULL
to	NULL
clarify	NULL
the	NULL
physiologic	NULL
role	NULL
of	NULL
transactivation	NULL
of	NULL
IL-2	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
in	NULL
HIV-1	NULL
infection	NULL
and	NULL
to	NULL
elucidate	NULL
the	NULL
molecular	NULL
mechanism	NULL
underlying	NULL
the	NULL
action	NULL
of	NULL
Tat	NULL
on	NULL
cellular	NULL
gene	NULL
expression	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
We	NULL
thank	NULL
E.	NULL
Serfling	NULL
,	NULL
K.	NULL
Khazaie	NULL
,	NULL
G.	NULL
Sczakiel	NULL
,	NULL
M.	NULL
Pawlita	NULL
,	NULL
and	NULL
H.	NULL
G.	NULL
Krausslich	NULL
for	NULL
vector	NULL
constructs	NULL
and	NULL
helpful	NULL
discussions	NULL
;	NULL
K.	NULL
Valerie	NULL
for	NULL
providing	NULL
the	NULL
HeLa-tat	NULL
cell	NULL
line	NULL
;	NULL
and	NULL
D.	NULL
Heiss	NULL
,	NULL
C.	NULL
Biirkle	NULL
,	NULL
and	NULL
M.	NULL
Kraft	NULL
for	NULL
expert	NULL
technical	NULL
assistance	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
grants	NULL
from	NULL
the	NULL
Bundesministerium	NULL
fiir	NULL
Forschung	NULL
und	NULL
Technologie	NULL
,	NULL
Bonn	NULL
,	NULL
Federal	NULL
Republic	NULL
of	NULL
Germany	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Arya	NULL
,	NULL
S.	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1986	NULL
.	NULL

Three	NULL
novel	NULL
genes	NULL
of	NULL
the	NULL
human	NULL
T-lymphotrophic	NULL
virus	NULL
type	NULL
III	NULL
:	NULL
immune	NULL
reactivity	NULL
of	NULL
their	NULL
products	NULL
with	NULL
sera	NULL
from	NULL
acquired	NULL
immune	NULL
deficiency	NULL
syndrome	NULL
patients	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
83:2209-2213	NULL
.	NULL

2	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
E.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
physiology	NULL
of	NULL
the	NULL
NF-	NULL
Â«	NULL
B	NULL
transcription	NULL
factor	NULL
,	NULL
p.	NULL
423	NULL
.	NULL

In	NULL
P.	NULL
Cohen	NULL
and	NULL
J.	NULL
G.	NULL
Foulkes	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Molecular	NULL
aspects	NULL
of	NULL
cellular	NULL
regulation	NULL
6	NULL
:	NULL
the	NULL
hormonal	NULL
control	NULL
of	NULL
gene	NULL
transcription	NULL
.	NULL

Elsevier	NULL
Science	NULL
Publishers	NULL
BV	NULL
,	NULL
Amsterdam	NULL
.	NULL

3	NULL
.	NULL

Berkhout	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
K.	NULL
T.	NULL
Jeang	NULL
.	NULL

1992	NULL
.	NULL

Functional	NULL
roles	NULL
for	NULL
the	NULL
TATA	NULL
promoter	NULL
and	NULL
enhancers	NULL
in	NULL
basal	NULL
and	NULL
Tat-induced	NULL
expression	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:139-149	NULL
.	NULL

4	NULL
.	NULL

Buonaguro	NULL
,	NULL
L.	NULL
,	NULL
G.	NULL
Barillari	NULL
,	NULL
H.	NULL
K.	NULL
Chang	NULL
,	NULL
C.	NULL
A.	NULL
Bohan	NULL
,	NULL
V.	NULL
Kao	NULL
,	NULL
R.	NULL
Morgan	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
B.	NULL
Ensoli	NULL
.	NULL

1992	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
inflammatory	NULL
cytokines	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:7159-7167	NULL
.	NULL

5	NULL
.	NULL

Chowdhury	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
P.	NULL
Taylor	NULL
,	NULL
C.-F.	NULL
Chang	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
and	NULL
K.	NULL
Khalili	NULL
.	NULL

1992	NULL
.	NULL

Evidence	NULL
that	NULL
a	NULL
sequence	NULL
similar	NULL
to	NULL
TAR	NULL
is	NULL
impor-	NULL
4184	NULL
6	NULL
.	NULL

10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

WESTENDORP	NULL
ET	NULL
AL	NULL
.	NULL

tant	NULL
for	NULL
induction	NULL
of	NULL
the	NULL
JC	NULL
virus	NULL
late	NULL
promoter	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:7355-7361	NULL
.	NULL

Clerici	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Shearer	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
Thl	NULL
-	NULL
>	NULL
Th2	NULL
switch	NULL
is	NULL
a	NULL
critical	NULL
step	NULL
in	NULL
the	NULL
etiology	NULL
of	NULL
HIV-1	NULL
infection	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
14:107-111.	NULL
.	NULL

Cleveland	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
M.	NULL
A.	NULL
Lopata	NULL
,	NULL
R.	NULL
J.	NULL
MacDonald	NULL
,	NULL
N.	NULL
J.	NULL
Cowan	NULL
,	NULL
W.	NULL
J.	NULL
Rutter	NULL
,	NULL
and	NULL
M.	NULL
W.	NULL
Kirschner	NULL
.	NULL

1980	NULL
.	NULL

Number	NULL
and	NULL
evolutionary	NULL
conservation	NULL
of	NULL
a-	NULL
and	NULL
B-tubulin	NULL
and	NULL
cytoplasmic	NULL
B-	NULL
and	NULL
y-actin	NULL
genes	NULL
using	NULL
specific	NULL
cloned	NULL
cDNA	NULL
probes	NULL
.	NULL

Cell	NULL
20:95-105.	NULL
.	NULL

Contente	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Csiszar	NULL
,	NULL
K.	NULL
Kenyon	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Friedman	NULL
.	NULL

1993	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
mouse	NULL
lysyl	NULL
oxidase	NULL
gene	NULL
.	NULL

Genomics	NULL
16:395-400.	NULL
.	NULL

Cross	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Feinberg	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Wolf	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
Leonard	NULL
.	NULL

1987	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
human	NULL
interleukin-2	NULL
receptor	NULL
alpha	NULL
chain	NULL
promoter	NULL
:	NULL
activation	NULL
of	NULL
a	NULL
nonfunctional	NULL
promoter	NULL
by	NULL
the	NULL
trans-activator	NULL
gene	NULL
of	NULL
HTLV-I	NULL
.	NULL

Cell	NULL
49:47-56	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1986	NULL
.	NULL

Regulation	NULL
of	NULL
HIV-1	NULL
gene	NULL
expression	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

5:2361-2368	NULL
.	NULL

Cullen	NULL
,	NULL
B.	NULL
R.	NULL
1993	NULL
.	NULL

Does	NULL
HIV-1	NULL
Tat	NULL
induce	NULL
a	NULL
change	NULL
in	NULL
viral	NULL
initiation	NULL
rights	NULL
?	NULL

Cell	NULL
73:417-420	NULL
.	NULL

Dingwall	NULL
,	NULL
C.	NULL
L.	NULL
,	NULL
I.	NULL
Ernberg	NULL
,	NULL
C.	NULL
H.	NULL
Chen	NULL
,	NULL
S.	NULL
M.	NULL
Green	NULL
,	NULL
S.	NULL
Heaphy	NULL
,	NULL
J.	NULL
Karn	NULL
,	NULL
A.	NULL
S.	NULL
Lowe	NULL
,	NULL
M.	NULL
Singh	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Skinner	NULL
.	NULL

1990	NULL
.	NULL

HIV-1	NULL
tat	NULL
protein	NULL
stimulates	NULL
transcription	NULL
by	NULL
binding	NULL
to	NULL
a	NULL
U-rich	NULL
buige	NULL
in	NULL
the	NULL
stem	NULL
of	NULL
the	NULL
TAR	NULL
RNA	NULL
structure	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

94145-4153	NULL
.	NULL

Embretson	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Zupancic	NULL
,	NULL
J.	NULL
L.	NULL
Ribas	NULL
,	NULL
A.	NULL
Burke	NULL
,	NULL
J.	NULL
Tenner-Racz	NULL
,	NULL
and	NULL
A.	NULL
T.	NULL
Haase	NULL
.	NULL

1993	NULL
.	NULL

Massive	NULL
covert	NULL
infection	NULL
of	NULL
helper	NULL
T	NULL
lymphocytes	NULL
and	NULL
macrophages	NULL
by	NULL
HIV	NULL
during	NULL
the	NULL
incubation	NULL
period	NULL
of	NULL
AIDS	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362:359-362	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
G.	NULL
Barillari	NULL
,	NULL
S.	NULL
Z.	NULL
Salahuddin	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
and	NULL
F.	NULL
Wong-Staal	NULL
.	NULL

1990	NULL
.	NULL

Tat	NULL
protein	NULL
of	NULL
HIV-1	NULL
stimulates	NULL
growth	NULL
of	NULL
cells	NULL
derived	NULL
from	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
lesions	NULL
of	NULL
AIDS	NULL
patients	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
345:84-86	NULL
.	NULL

Ensoli	NULL
,	NULL
B.	NULL
,	NULL
L.	NULL
Buonaguro	NULL
,	NULL
G.	NULL
Barillari	NULL
,	NULL
V.	NULL
Fiorelli	NULL
,	NULL
R.	NULL
Gendelman	NULL
,	NULL
R.	NULL
A.	NULL
Morgan	NULL
,	NULL
P.	NULL
Wingfield	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1993	NULL
.	NULL

Release	NULL
,	NULL
uptake	NULL
,	NULL
and	NULL
effects	NULL
of	NULL
extracellular	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
on	NULL
cell	NULL
growth	NULL
and	NULL
viral	NULL
transactivation	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:277-287	NULL
.	NULL

Feinberg	NULL
,	NULL
M.	NULL
B.	NULL
,	NULL
D.	NULL
Baltimore	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Frankel	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
role	NULL
of	NULL
Tat	NULL
in	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
life	NULL
cycle	NULL
indicates	NULL
a	NULL
primary	NULL
effect	NULL
on	NULL
transcriptional	NULL
elongation	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
88:4045-4049	NULL
.	NULL

Felber	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
H.	NULL
Paskalis	NULL
,	NULL
C.	NULL
Kleinmann-Ewing	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
G.	NULL
N.	NULL
Pavlakis	NULL
.	NULL

1985	NULL
.	NULL

The	NULL
pX	NULL
protein	NULL
of	NULL
HTLV-1	NULL
is	NULL
a	NULL
transcriptional	NULL
activator	NULL
of	NULL
its	NULL
long	NULL
terminal	NULL
repeat	NULL
.	NULL

Science	NULL
229	NULL
:	NULL
675-679	NULL
.	NULL

Flores	NULL
,	NULL
S.	NULL
C.	NULL
,	NULL
J.	NULL
C.	NULL
Marecki	NULL
,	NULL
K.	NULL
P.	NULL
Harper	NULL
,	NULL
S.	NULL
K.	NULL
Bose	NULL
,	NULL
S.	NULL
K.	NULL
Nelson	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
McCord	NULL
.	NULL

1993	NULL
.	NULL

Tat	NULL
protein	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
represses	NULL
expression	NULL
of	NULL
manganese	NULL
superoxide	NULL
dismutase	NULL
in	NULL
Hela	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:7632-7636	NULL
.	NULL

18a.Frank	NULL
,	NULL
R.	NULL
W.	NULL
,	NULL
et	NULL
al	NULL
.	NULL

Unpublished	NULL
data	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

Frankel	NULL
,	NULL
A.	NULL
D.	NULL
,	NULL
and	NULL
C.	NULL
O.	NULL
Pabo	NULL
.	NULL

1988	NULL
.	NULL

Cellular	NULL
uptake	NULL
of	NULL
the	NULL
tat	NULL
protein	NULL
from	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

Cell	NULL
55:1189-1193	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Irving	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
251:313-316	NULL
.	NULL

Garcia	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
F.	NULL
A.	NULL
Wu	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
B.	NULL
Gaynor	NULL
.	NULL

1987	NULL
.	NULL

Interaction	NULL
of	NULL
cellular	NULL
proteins	NULL
involved	NULL
in	NULL
the	NULL
transcriptional	NULL
regulation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

6:3761-3770	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
1985	NULL
.	NULL

High	NULL
efficiency	NULL
gene	NULL
transfer	NULL
into	NULL
mammalian	NULL
cells	NULL
,	NULL
p.	NULL
143	NULL
.	NULL

In	NULL
D.	NULL
M.	NULL
Glover	NULL
(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
DNA	NULL
cloning	NULL
,	NULL
vol	NULL
.	NULL

II	NULL
.	NULL

IRL	NULL
press	NULL
,	NULL
Washington	NULL
,	NULL
D.C.	NULL
Gough	NULL
,	NULL
N.	NULL
M.	NULL
1988	NULL
.	NULL

Rapid	NULL
and	NULL
quantitative	NULL
preparation	NULL
of	NULL
cytoplasmic	NULL
RNA	NULL
from	NULL
small	NULL
numbers	NULL
of	NULL
cells	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

173:93-95	NULL
.	NULL

Harrich	NULL
,	NULL
D.	NULL
,	NULL
J.	NULL
Garcia	NULL
,	NULL
R.	NULL
Mitsuyasu	NULL
,	NULL
and	NULL
R.	NULL
Gaynor	NULL
.	NULL

1990	NULL
.	NULL

TAR	NULL
independent	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
in	NULL
phorbol	NULL
ester	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

9:4417-4423	NULL
.	NULL

Hauber	NULL
,	NULL
J.	NULL
,	NULL
A.	NULL
Perkins	NULL
,	NULL
E.	NULL
P.	NULL
Heimer	NULL
,	NULL
and	NULL
B.	NULL
R.	NULL
Cullen	NULL
.	NULL

1987	NULL
.	NULL

Trans-activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gene	NULL
expression	NULL
is	NULL
mediated	NULL
by	NULL
nuclear	NULL
events	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:6364-6368	NULL
.	NULL

Howkroft	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
K.	NULL
Strebel	NULL
,	NULL
M.	NULL
A.	NULL
Martin	NULL
,	NULL
and	NULL
D.	NULL
S.	NULL
Singer	NULL
.	NULL

1993	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

J.	NULL
Repression	NULL
of	NULL
MHC	NULL
class	NULL
I	NULL
gene	NULL
promoter	NULL
by	NULL
two-exon	NULL
Tat	NULL
of	NULL
HIV	NULL
.	NULL

Science	NULL
260:1320-1322	NULL
.	NULL

Jeang	NULL
,	NULL
K.-T.	NULL
,	NULL
R.	NULL
Chun	NULL
,	NULL
N.	NULL
H.	NULL
Lin	NULL
,	NULL
A.	NULL
Gatignol	NULL
,	NULL
C.	NULL
G.	NULL
Glabe	NULL
,	NULL
and	NULL
H.	NULL
Fan	NULL
.	NULL

1993	NULL
.	NULL

In	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
binding	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
Tat	NULL
protein	NULL
and	NULL
Spl	NULL
transcription	NULL
factor	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:6224-6233	NULL
.	NULL

Jones	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

1993	NULL
.	NULL

Tat	NULL
and	NULL
the	NULL
HIV-1	NULL
promoter	NULL
.	NULL

Curr	NULL
.	NULL

Opin	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:461-468	NULL
.	NULL

Kahn	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
J.	NULL
Wei	NULL
,	NULL
C.	NULL
Borner	NULL
,	NULL
K.	NULL
O'Driscoll	NULL
,	NULL
and	NULL
B.	NULL
Weinstein	NULL
.	NULL

1990	NULL
.	NULL

Construction	NULL
of	NULL
defined	NULL
deletion	NULL
mutants	NULL
by	NULL
thermal	NULL
cycled	NULL
fusion	NULL
:	NULL
applications	NULL
to	NULL
protein	NULL
kinase	NULL
C.	NULL
Technique	NULL
2	NULL
(	NULL
I	NULL
)	NULL
:27	NULL
.	NULL

Kamine	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
G.	NULL
Chinnadurai	NULL
.	NULL

1992	NULL
.	NULL

Synergistic	NULL
activation	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
promoter	NULL
by	NULL
the	NULL
viral	NULL
Tat	NULL
protein	NULL
and	NULL
cellular	NULL
transcription	NULL
factor	NULL
Sp1	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

66:3932-3936	NULL
.	NULL

Kim	NULL
,	NULL
Y.-S.	NULL
,	NULL
J.	NULL
H.	NULL
Kehrl	NULL
,	NULL
J.	NULL
Burton	NULL
,	NULL
C.	NULL
L.	NULL
Tendler	NULL
,	NULL
K.	NULL
T.	NULL
Jeang	NULL
,	NULL
D.	NULL
Danielpour	NULL
,	NULL
C.	NULL
Thevenin	NULL
,	NULL
K.	NULL
Y.	NULL
Kim	NULL
,	NULL
M.	NULL
B.	NULL
Sporn	NULL
,	NULL
and	NULL
A	NULL
.	NULL

B.	NULL
Roberts	NULL
.	NULL

1990	NULL
.	NULL

Transactivation	NULL
of	NULL
the	NULL
transforming	NULL
growth	NULL
factor	NULL
B1	NULL
(	NULL
TGF-B1	NULL
)	NULL
gene	NULL
by	NULL
human	NULL
T	NULL
lymphotropic	NULL
virus	NULL
type	NULL
I	NULL
Tax	NULL
:	NULL
a	NULL
potential	NULL
mechanism	NULL
for	NULL
the	NULL
increased	NULL
production	NULL
of	NULL
TGF-B1	NULL
in	NULL
adult	NULL
T-cell	NULL
leukemia	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:121-129	NULL
.	NULL

Kim	NULL
,	NULL
Y.-S.	NULL
,	NULL
and	NULL
R.	NULL
Risser	NULL
.	NULL

1993	NULL
.	NULL

TAR-independent	NULL
transactivation	NULL
of	NULL
the	NULL
murine	NULL
cytomegalovirus	NULL
major	NULL
immediate-early	NULL
promoter	NULL
by	NULL
the	NULL
Tat	NULL
protein	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

67:239-248	NULL
.	NULL

Lane	NULL
,	NULL
H.	NULL
C.	NULL
,	NULL
H.	NULL
Masur	NULL
,	NULL
M.	NULL
S.	NULL
Edgar	NULL
,	NULL
G.	NULL
Whalen	NULL
,	NULL
A.	NULL
H.	NULL
Rook	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1983	NULL
.	NULL

Abnormalities	NULL
of	NULL
B-cell	NULL
activation	NULL
and	NULL
immunodeficiency	NULL
syndrome	NULL
.	NULL

N.	NULL
Engl	NULL
.	NULL

J.	NULL
Med	NULL
.	NULL

309:453-458	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
A.	NULL
Kuang	NULL
,	NULL
A.	NULL
Gifford	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

NF-	NULL
Â«	NULL
B	NULL
protein	NULL
purification	NULL
from	NULL
bovine	NULL
spleen	NULL
:	NULL
nucleotide	NULL
stimulation	NULL
and	NULL
binding	NULL
site	NULL
specificity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:8825-8829	NULL
.	NULL

Leung	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1988	NULL
.	NULL

HTLV-1	NULL
transactivator	NULL
induces	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
through	NULL
an	NULL
NF-kappa	NULL
B-like	NULL
factor	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:776-778	NULL
.	NULL

Lotz	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Keckow	NULL
,	NULL
M.	NULL
T.	NULL
Cronin	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
McCutchan	NULL
,	NULL
L	NULL
Clark-Lewis	NULL
,	NULL
D.	NULL
A.	NULL
Carons	NULL
,	NULL
and	NULL
W.	NULL
Wachsman	NULL
.	NULL

1990	NULL
.	NULL

Induction	NULL
of	NULL
transforming	NULL
growth	NULL
factor	NULL
B	NULL
(	NULL
TGFB	NULL
)	NULL
by	NULL
HIV-1	NULL
Tat	NULL
;	NULL
a	NULL
noncyto-pathic	NULL
pathway	NULL
of	NULL
immunodeficiency	NULL
in	NULL
HIV	NULL
infection	NULL
.	NULL

FASEB	NULL
J	NULL
.	NULL

4:1861	NULL
.	NULL

Luckow	NULL
,	NULL
B.	NULL
,	NULL
and	NULL
G.	NULL
Schiitz	NULL
.	NULL

1987	NULL
.	NULL

CAT	NULL
constructions	NULL
with	NULL
multiple	NULL
unique	NULL
restriction	NULL
sites	NULL
for	NULL
the	NULL
functional	NULL
analysis	NULL
of	NULL
eukaryotic	NULL
promoters	NULL
and	NULL
regulatory	NULL
elements	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

15:5490	NULL
.	NULL

Mann	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Frankel	NULL
.	NULL

1991	NULL
.	NULL

Endocytosis	NULL
and	NULL
targeting	NULL
of	NULL
exogenous	NULL
HIV-1	NULL
Tat	NULL
protein	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

10:1733-1739	NULL
.	NULL

Minami	NULL
,	NULL
Y.	NULL
,	NULL
T.	NULL
Kono	NULL
,	NULL
T.	NULL
Miyazaki	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
IL-2	NULL
receptor	NULL
complex	NULL
:	NULL
its	NULL
structure	NULL
,	NULL
function	NULL
and	NULL
target	NULL
genes	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

11:245-267	NULL
.	NULL

Morgan	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
F.	NULL
W.	NULL
Ruscetti	NULL
,	NULL
and	NULL
R.	NULL
C.	NULL
Gallo	NULL
.	NULL

1976	NULL
.	NULL

Selective	NULL
in	NULL
vitro	NULL
growth	NULL
of	NULL
T	NULL
lymphocytes	NULL
from	NULL
normal	NULL
human	NULL
bone	NULL
marrows	NULL
.	NULL

Science	NULL
193:1007-1008	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.	NULL
S.	NULL
Ahuja	NULL
,	NULL
S.	NULL
M.	NULL
Najjar	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
.	NULL

1993	NULL
.	NULL

Negative	NULL
transcriptional	NULL
regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
by	NULL
glucocorticoids	NULL
through	NULL
interference	NULL
with	NULL
nuclear	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

91:1481-1489	NULL
.	NULL

Pantaleo	NULL
,	NULL
G.	NULL
,	NULL
C.	NULL
Graziosi	NULL
,	NULL
H.	NULL
F.	NULL
Demarest	NULL
,	NULL
L.	NULL
Butini	NULL
,	NULL
M.	NULL
Montroli	NULL
,	NULL
C.	NULL
H.	NULL
Fox	NULL
,	NULL
J.	NULL
M.	NULL
Orenstein	NULL
,	NULL
D.	NULL
P.	NULL
Kotler	NULL
,	NULL
and	NULL
A.	NULL
S.	NULL
Fauci	NULL
.	NULL

1993	NULL
.	NULL

HIV	NULL
infection	NULL
is	NULL
active	NULL
and	NULL
progressive	NULL
in	NULL
lymphoid	NULL
tissue	NULL
during	NULL
the	NULL
clinically	NULL
latent	NULL
stage	NULL
of	NULL
the	NULL
disease	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
362	NULL
:	NULL
355-358	NULL
.	NULL

Purvis	NULL
,	NULL
S.	NULL
F.	NULL
,	NULL
D.	NULL
L.	NULL
Georges	NULL
,	NULL
T.	NULL
M.	NULL
Williams	NULL
,	NULL
and	NULL
M.	NULL
M.	NULL
Lederman	NULL
.	NULL

1992	NULL
.	NULL

Suppression	NULL
of	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
expression	NULL
in	NULL
Jurkat	NULL
cells	NULL
stably	NULL
expressing	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
protein	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

144:32-42.	NULL
.	NULL

Remenick	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
F.	NULL
Radonovich	NULL
,	NULL
and	NULL
J.	NULL
N.	NULL
Brady	NULL
.	NULL

1991	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
Tat	NULL
transactivation	NULL
:	NULL
induction	NULL
of	NULL
a	NULL
tissue-specific	NULL
enhancer	NULL
in	NULL
a	NULL
nonpermissive	NULL
cell	NULL
line	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

65:5641-5646	NULL
.	NULL

Rittner	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
G.	NULL
Sczakiel	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
and	NULL
analysis	NULL
of	NULL
antisense	NULL
RNA	NULL
target	NULL
regions	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

19:1421-1426	NULL
.	NULL

Rittner	NULL
,	NULL
K.	NULL
,	NULL
H.	NULL
Stoppler	NULL
,	NULL
M.	NULL
Pawlita	NULL
,	NULL
and	NULL
G.	NULL
Sczakiel	NULL
.	NULL

1991	NULL
.	NULL

Versatile	NULL
eukaryotic	NULL
vectors	NULL
for	NULL
strong	NULL
and	NULL
constitutive	NULL
transient	NULL
VoL	NULL
.	NULL

68	NULL
,	NULL
1994	NULL
47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55.	NULL
and	NULL
stable	NULL
expression	NULL
.	NULL

Methods	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:176-181	NULL
.	NULL

Sambrook	NULL
,	NULL
J.	NULL
,	NULL
E.	NULL
F.	NULL
Fritsch	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1989	NULL
.	NULL

Molecular	NULL
cloning	NULL
:	NULL
a	NULL
laboratory	NULL
manual	NULL
,	NULL
2nd	NULL
ed	NULL
.	NULL

Cold	NULL
Spring	NULL
Harbor	NULL
Labo-ratory	NULL
,	NULL
Cold	NULL
Spring	NULL
Harbor	NULL
,	NULL
N.Y.	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
13:136-142	NULL
.	NULL

Selby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1990	NULL
.	NULL

Trans-activation	NULL
by	NULL
HIV-1	NULL
Tat	NULL
via	NULL
a	NULL
heterologous	NULL
RNA	NULL
binding	NULL
protein	NULL
.	NULL

Cell	NULL
62:769-776	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Barthelm	NULL
@	NULL
s	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
B.	NULL
Schenk	NULL
,	NULL
S.	NULL
Zarius	NULL
,	NULL
R.	NULL
Swoboda	NULL
,	NULL
F.	NULL
Merkurio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Ubiquitous	NULL
and	NULL
lymphocyte-specific	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
mouse	NULL
interleukin	NULL
2	NULL
gene	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

8:465	NULL
.	NULL

Shibuya	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1989	NULL
.	NULL

Identification	NULL
of	NULL
multiple	NULL
cis-elements	NULL
and	NULL
trans-acting	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
induced	NULL
expression	NULL
of	NULL
human	NULL
IL-2	NULL
gene	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

17:9173-9184	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
C.	NULL
A.	NULL
Norris	NULL
,	NULL
M.	NULL
Kamoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interleukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042-3049	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
B.	NULL
Feinberg	NULL
,	NULL
N.	NULL
Holbrook	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
interleukin-2	NULL
and	NULL
interleukin-2	NULL
receptor	NULL
(	NULL
Tac	NULL
)	NULL
promoter	NULL
expression	NULL
by	NULL
the	NULL
trans-activator	NULL
(	NULL
tat	NULL
)	NULL
gene	NULL
product	NULL
of	NULL
human	NULL
T	NULL
cell	NULL
leukemia	NULL
virus	NULL
type	NULL
I.	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
,	NULL
USA	NULL
$	NULL
4:5389-5393	NULL
.	NULL

Siekevitz	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
F.	NULL
Josephs	NULL
,	NULL
M.	NULL
Dukovich	NULL
,	NULL
N.	NULL
Peffer	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
HIV-1	NULL
LTR	NULL
by	NULL
T	NULL
cell	NULL
mitogens	NULL
and	NULL
the	NULL
transactivator	NULL
protein	NULL
of	NULL
HTLV-1	NULL
.	NULL

Science	NULL
238:1575-1578	NULL
.	NULL

Sodroski	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
Patarca	NULL
,	NULL
and	NULL
C.	NULL
Rosen	NULL
.	NULL

1985	NULL
.	NULL

Location	NULL
of	NULL
the	NULL
56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

59	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

HIV-1	NULL
Tat	NULL
UPREGULATES	NULL
IL-2	NULL
EXPRESSION	NULL
4185	NULL
transacting	NULL
region	NULL
on	NULL
the	NULL
genome	NULL
of	NULL
human	NULL
T-lymphotrophic	NULL
virus	NULL
type	NULL
III	NULL
.	NULL

Science	NULL
229:74-77	NULL
.	NULL

Taniguchi	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Matsui	NULL
,	NULL
T.	NULL
Fujita	NULL
,	NULL
C.	NULL
Takaoka	NULL
,	NULL
N.	NULL
Kashima	NULL
,	NULL
R.	NULL
Yoshimoto	NULL
,	NULL
and	NULL
J.	NULL
Hamuro	NULL
.	NULL

1983	NULL
.	NULL

Structure	NULL
and	NULL
expression	NULL
of	NULL
a	NULL
cloned	NULL
cDNA	NULL
for	NULL
human	NULL
interleukin-2	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
302:302-310	NULL
.	NULL

Taylor	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
R.	NULL
Pomerantz	NULL
,	NULL
O.	NULL
Bagasra	NULL
,	NULL
M.	NULL
Chowdhury	NULL
,	NULL
J.	NULL
Rappaport	NULL
,	NULL
K.	NULL
Khalili	NULL
,	NULL
and	NULL
S.	NULL
Amini	NULL
.	NULL

1992	NULL
.	NULL

TAR-independent	NULL
transactivation	NULL
by	NULL
Tat	NULL
in	NULL
cells	NULL
derived	NULL
from	NULL
the	NULL
CNS	NULL
:	NULL
a	NULL
novel	NULL
mechanism	NULL
of	NULL
HIV-1	NULL
gene	NULL
regulation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

11:3395-3403	NULL
.	NULL

Tong-Starksen	NULL
,	NULL
S.	NULL
E.	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
B.	NULL
M.	NULL
Peterlin	NULL
.	NULL

1987	NULL
.	NULL

Human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
responds	NULL
to	NULL
T-cell	NULL
activation	NULL
signals	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84:6845-6849	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
Northrop	NULL
,	NULL
A.	NULL
Admon	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1993	NULL
.	NULL

Jun	NULL
family	NULL
members	NULL
are	NULL
controlled	NULL
by	NULL
a	NULL
calcium-regulated	NULL
,	NULL
cyclosporin-A-sensitive	NULL
signaling	NULL
pathway	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

7:188-196.	NULL
.	NULL

Valerie	NULL
,	NULL
K.	NULL
,	NULL
A.	NULL
Delers	NULL
,	NULL
C.	NULL
Bruck	NULL
,	NULL
C.	NULL
Thiriart	NULL
,	NULL
H.	NULL
Rosenberg	NULL
,	NULL
C.	NULL
Debouck	NULL
,	NULL
and	NULL
M.	NULL
Rosenberg	NULL
.	NULL

1988	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
type	NULL
1	NULL
by	NULL
DNA	NULL
damage	NULL
in	NULL
human	NULL
cells	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
333:78-81	NULL
.	NULL

Viscidi	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
K.	NULL
Mayur	NULL
,	NULL
H.	NULL
M.	NULL
Lederman	NULL
,	NULL
and	NULL
A.	NULL
D.	NULL
Frankel	NULL
.	NULL

1989	NULL
.	NULL

Inhibition	NULL
of	NULL
antigen-induced	NULL
lymphocyte	NULL
proliferation	NULL
by	NULL
Tat	NULL
protein	NULL
from	NULL
HIV-1	NULL
.	NULL

Science	NULL
246:1606-1608	NULL
.	NULL

Vogel	NULL
,	NULL
J.	NULL
,	NULL
S.	NULL
H.	NULL
Hinrichs	NULL
,	NULL
R.	NULL
K.	NULL
Reynolds	NULL
,	NULL
P.	NULL
A.	NULL
Luciw	NULL
,	NULL
and	NULL
G.	NULL
Jay	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
HIV	NULL
tat	NULL
gene	NULL
induces	NULL
dermal	NULL
lesions	NULL
resembling	NULL
Kaposi	NULL
's	NULL
sarcoma	NULL
in	NULL
transgenic	NULL
mice	NULL
.	NULL

Nature	NULL
(	NULL
London	NULL
)	NULL
335:606-611	NULL
.	NULL

Wano	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Feinberg	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Hosking	NULL
,	NULL
H.	NULL
Bogerd	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Green	NULL
.	NULL

1988	NULL
.	NULL

Stable	NULL
expression	NULL
of	NULL
the	NULL
tax	NULL
gene	NULL
of	NULL
type	NULL
I	NULL
human	NULL
T-cell	NULL
leukemia	NULL
virus	NULL
in	NULL
human	NULL
T	NULL
cells	NULL
activates	NULL
specific	NULL
cellular	NULL
genes	NULL
involved	NULL
in	NULL
growth	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85:9733-9737	NULL
.	NULL

